Rapid cell purification systems

Abstract
Methods and systems for purifying cells and/or viruses are provided. The sample is added to a well disposed in a medium. A potential is applied across the medium to cause the contaminants to enter one or more walls of the well, and retain the cells and/or viruses in the well. The cells and/or viruses can be removed from the well, and optionally adhered or fixed to a surface, or detected. In one embodiment, the cells and/or viruses may be retained in the well by embedding in the medium. The medium including the embedded cells and/or viruses may be excised or otherwise removed and transferred to a glass slide or other solid surface.
Description
FIELD

This disclosure relates to methods and systems for purifying cells and/or viruses, particularly microorganisms in a sample, particularly in preparation for diagnostics systems.


BACKGROUND

Diagnostic systems that detect cells and/or viruses are of clinical and diagnostic interest. Detection of cells and/or viruses is often prevented or complicated by the presence of contaminants that interfere with collection or detection of the cells and/or viruses. This may be particularly true for cells or viruses that are adhered or fixed to a solid surface prior to detection.


Additionally, operator variability may adversely impact the quality of specimen. Specimen quality is dependent on patient factors including but not limited to differences between patients, and the presence or absence of various interfering substances. In many cases, the specimen is split and analyzed using various diagnostic tests. Therefore, purifying samples reliably and cost-effectively to remove inhomogeneities helps to improve the likelihood of relevant statistical sampling of cells and/or viruses therein.


SUMMARY

Methods and systems for purifying a microorganism are provided. The sample is added to a well disposed in a medium. A potential is applied across the medium to cause the contaminants to enter one or more walls of the well, while the cells and/or viruses are retained in the well. The cells and/or viruses can be removed from the well, and optionally adhered or fixed to a surface, or detected. In one embodiment, the cells and/or viruses may be retained in the well by embedding in the medium. The medium including the embedded cells and/or viruses may be excised or otherwise removed and transferred to a glass slide or other solid surface. The medium may then be cut or sectioned to correspond to the respective wells. The medium is then dried, Gram stained, and the cells/viruses detected.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of an embodiment of a system used to purify a microorganism.



FIG. 2A is a perspective view of an embodiment of a medium in a cassette which may be used with the system of FIG. 1.



FIG. 2B is a partial perspective view of another embodiment of a medium in a cassette which may be used with the system of FIG. 1.



FIG. 2C depicts a side view of the medium and system of FIG. 2B.



FIGS. 2D and 2E illustrate excision of a portion of the medium of FIG. 2B.



FIGS. 2F, 2G and 2H depict the excised portion of the medium of FIGS. 2D and 2E on a solid surface.



FIG. 2I depicts Gram stained microorganisms that may be detected in accordance with the systems and methods described herein.



FIG. 2J is a top view of a medium in a cassette which may be used with the system of FIG. 1, wherein a localization device is used to localize the cells and/or viruses.



FIG. 2K depicts Gram stained microorganisms that may be detected in accordance with the systems and methods described herein.



FIG. 3 is a side view of an embodiment of a custom well-forming comb used to make wells in a medium.



FIGS. 4A and 4B are a perspective view of multiple flow cell laminate assembly and a single flow cell cutaway view with corresponding electrode and circuit details used to create a potential across a medium.



FIG. 5 is a graph showing results of accumulated objects (solid materials immobilized on a surface) over time for treated compared to non-treated samples.



FIGS. 6A, 6B and 6C depict microscopic images of non-treated samples over time.



FIGS. 7A, 7B and 7C depict microscopic images of treated samples over time.



FIG. 8 is a side view of an embodiment of a circular well formed in a medium with corresponding electrodes



FIG. 9 is a side view of an embodiment of a chamber formed in the medium with an inlet and outlet port enabling sample recirculation.





DETAILED DESCRIPTION

Described herein are various embodiments of systems and methods for purifying cells and/or viruses in a sample. A sample containing cells and/or viruses is added to a well disposed in a medium. A potential is applied across the medium to cause contaminants to enter the medium through one or more walls of said well which retain the cells and/or viruses in the well. The cells and/or viruses are then removed from the well. The cells and/or viruses may also remain in or on the wall of the well, and/or the wall/well may be excised for further analysis.


The systems and methods described herein may concentrate cells and/or viruses from a low content specimen or sample in the wells, thereby removing or reducing potentially interfering debris and resulting in more readable specimens. For example, the disclosed methods and systems may be used in testing of CSF (cerebro-spinal fluid) specimens or other hypocellular specimens. In such samples, bacterial organisms can be localized in 5×5 field of view capture areas (100× objective magnification) to minimize time-consuming searching during microscopic examination. A system having multiple wells may also be used to support parallel processing of sample aliquots for concurrent analyses by multiple downstream methods.


An exemplary embodiment of the system is depicted in FIG. 1. FIG. 1 depicts a system 100 used to purify cells and/or viruses with a cassette 106 configured to receive a medium. The cassette 106 includes a bottom plate 108 and sides 110. Negative electrode 102 and positive electrode 104 are operably connected to the medium through a buffer (not shown) placed in a reservoir 112.


The sample is added to a well disposed in a medium, preferably formed in the medium. In some embodiments, a plastic well may also be disposed in the medium, in addition to well(s) formed in the medium. An electrical potential is applied to the well causing contaminant material to enter the medium while the cells and/or viruses accumulate on the wall of the well. In some embodiments, the cells and/or viruses may be localized on the wall of the well. Cells and/or viruses remain in the well, thereby purifying the sample. The sample may be mixed during or after a time period of the applied electric field. In some embodiments, the process can be repeated until separation of contaminants that interfere with adhesion to a detection surface has been achieved. The well can then be rinsed, and cells and/or viruses recovered. In some embodiments, the wall of the well where the cells and/or viruses have accumulated may be excised or otherwise removed from the rest of the gel medium. Alternatively, the electrical potential can be briefly reversed in polarity to displace the cells and/or viruses from the wall prior to rinsing and recovery. Mixing, applying a potential, and/or reversing polarity of applied field can be performed iteratively to further purify the sample.


In some embodiments, the sample volume recovered is less than, and sometimes substantially less than, the initial sample volume in the wells. In one embodiment, a barrier, such as an impermeable plastic sheet, is inserted into the wells and used to reduce the volume in the wells, thereby further concentrating the cells and/or viruses in the well and providing a reduced sample volume for recovery.


Systems, including electrophoresis boxes and electrodes, can be obtained from Thermo Fisher (Waltham, Mass.) under the EC-Apparatus brand name (e.g., product number EC 250-90).



FIG. 2A depicts an embodiment of a medium in a cassette 106 comprising a bottom plate 108 and sides 110, which may be used with the system 100. A medium 220 is disposed in the cassette 106 with a plurality of wells 222 in the medium 220. A sample 224 is added in some wells 222 with a pipette 226 comprising a pipette tip 228. Although the medium is shown as a top load gel slab, media in other forms, including but not limited to vertical gel slabs, can be used.



FIGS. 2B-2H illustrate an embodiment where a medium 220 is disposed in a cassette 106 and has a plurality of wells 222 in the medium 220. A sample is added and a potential is applied between negative electrode 102 and positive electrode 104 as described elsewhere herein to cause contaminant material to enter the medium while the cells 201 and/or viruses accumulate or become embedded on the wall 223 of the well 222, depicted in FIG. 2C as concentrated cells 202. As shown in FIGS. 2D-2E, a portion 230 of the medium 220, including at least a portion of the wells 222, is excised, such as by cutting the medium along planes of excision defined by lines A-A′ and B-B′, or otherwise removed from the medium. In some embodiments, the excision can be robotically automated.


Following excision, the excised portion of the medium may be fixed, for example, for staining or extracting molecular samples for analysis. In some embodiments, and as shown in FIGS. 2F and 2G, the excised portion 230 may be placed on a solid surface 232, such as a glass slide, and the excised portion 230 may be sectioned at each well 222 into sections 231. The sections 231 of excised portion 230 may be dried, Gram stained, and detected as indicated in FIGS. 2H-2I. In some embodiments, a prepared slide (e.g., wherein the sectioned, excised portion has been dried) can be introduced into automated Gram staining equipment.


In some embodiments, the cells and/or viruses may be localized on the wall of the well by, or with the help of, a localization device. FIGS. 2J and 2K depict an embodiment illustrating a localization device 240 and localized cells 241. FIG. 2J is a top view of a gel medium that utilizes non-conductive materials as a localization device to distort the electric field resulting in localized concentration of cells and/or viruses, such as microorganisms. FIG. 2J illustrates an embodiment where the medium 220 is disposed in the cassette 106 showing a plurality of wells 222, including a plastic well 224, in the medium 220. The medium 220 includes a proximal end 220a and a distal end 220b. Disposed between the wells 222 and the medium 220 is a localization device 240 comprising a non-conductive material including at least one hole or aperture 240a. A sample is added and a potential is applied as described elsewhere herein to cause contaminant material to enter the medium while the cells and/or viruses accumulate or become embedded on the wall 223 of the well 222. In this embodiment, the sample flows through the aperture 240a in the non-conductive localization device 240, thereby localizing the cells and/or viruses that accumulate or become embedded on the wall 223 of the well 222, as described with reference to FIG. 2C. In this embodiment, the non-conductive localization device 240 prevents or inhibits the sample from flowing anywhere but through the aperture(s) 240a. In one embodiment, the non-conductive material may be a plastic film. As described above with reference to FIGS. 2D-2I, a portion of the medium 220, including at least a portion of the wells 222, is excised or otherwise removed. The excised portion 230 may be placed on a solid surface 232, such as a glass slide, and may be dried, Gram stained, and detected. FIG. 2K depicts Gram stained localized microorganisms 241 that have been localized in accordance with the methods and systems described herein.


While FIGS. 2J and 2K depict an embodiment of a system and method for localization using a localization device 240 comprising non-conductive materials, other methods and devices for localization may also be used. In one embodiment, the localization device is a conductive material, such as a metal or metal alloy wire, that is embedded in or placed near a distal end 220b of the medium 220 (i.e., downstream relative to the direction of migration). When a potential is applied, the cells and/or viruses localize on the wall of the well in a location corresponding to the position of the conductive material. That is, where the conductive material is a straight metal wire, the cells and/or viruses localize on the wall of the well in a straight line corresponding to the line of the metal wire. In another embodiment, the localization device includes large and small (or discrete) electrodes are used. For example, a large electrode, such as a sheet electrode, may be placed at a proximal location relative to the proximal end 220a of the medium 220. A small electrode may be placed at a distal location relative to the distal end 220b of the medium 220. When a potential is applied, the cells and/or viruses localize on the wall of the well in a location corresponding to the location of the small electrode. In still other embodiments, the localization device is a discontinuous buffer system. In such a system, the conductivity inside the well is different from the conductivity outside the well. For example, where a well is made of the medium, the conductivity of the sample and the conductivity of the well are different. When a potential is applied, the cells and/or viruses localize on the wall of the well due, at least in part, to this conductivity difference.


Dyes can be used in samples to pre-label or added to provide a tracking dye for purposes of a quantitative reference or sample transfer quality control indicator. Examples of dyes include colorants, bio-active adjuncts such as labeled antibodies, vital stains, mortal stains (such as propidium iodide and the like). Zwitterionic or neutrally charged dye molecules can be used to monitor electro-osmotic flow.


The potential applied across the medium effective for removal of contaminants can be applied for a variable time and is dependent on the sample conductivity. For samples retrieved using normal saline and having a conductivity near that of normal saline, for example, the potential can be applied from 1 to 60 minutes.


In some embodiments, the method includes an asymmetric alternating potential. In other embodiments, the potential is a constant potential. In various embodiments, the applied potential induces electro-osmotic flow that is used to remove contaminants having a neutral charge. The potential can be reversed in polarity to displace cells and/or viruses from the surface of the medium. In some embodiments, the method includes applying a tangential flow across the medium to remove non-permeable contaminants from the surface of the medium. The tangential flow may be applied by flowing the sample over the medium. The tangential flow may be generated using additional buffer that is not the sample. The flow can be continuously cycled over the medium.


When a sample is taken from a patient, there are various components in the sample. For example, in a patient suffering from pneumonia, a sample may include saline, anionic and cationic species, pulmonary surfactants, bacteria, mucus, blood, host cells such as white blood cells, and/or lung tissue cells. Mucus components include, but are not limited to, mucoidal glycoproteins, proteins, extra-cellular nucleic acids, F-actin, lysed white blood cell fragments. Blood components may include, but are not limited to, red cells, white cells, platelets, and plasma. Plasma components may include, but are not limited to, sugar, fat, protein and salt solution, platelets, blood clotting factors, sugars, lipids, vitamins, minerals, hormones, enzymes, antibodies, and other proteins including heme, albumins, immunoglobulins, fibrinogens, regulatory proteins, lipoproteins (chylomicrons, VLDL, LDL, HDL), transferrin, prothrombin, enzymes, proenzymes, residual antibiotics used to treat the patient, and hormones. Lung tissue components include host epithelial cells (intact or lysed). The cells in the alveolar walls of the lung produce and secrete pulmonary surfactant. Pulmonary surfactant is a mixture of phospholipids and proteins. White blood cells may also be present in lung samples. All the above components may be solubilized.


In some embodiments, the cells include blood cells, fungal cells, bacterial cells, or microorganisms including parasites. Examples of blood cells include red blood cells and white blood cells. In some variations, the white blood cells can be neutrophils.


In various embodiments, microorganisms can include bacteria, fungi, algae, and protozoa. In one aspect, the microorganisms are bacteria. The microorganisms can be pathogenic to humans and animals. Suitable microorganisms include any of those well established in the medical art and those novel pathogens and variants that emerge from time to time. Examples of currently known bacteria include, but are not limited to, genera such as Bacillus, Vibrio, Escherichia, Shigella, Salmonella, Mycobacterium, Clostridium, Cornyebacterium, Streptococcus, Staphylococcus, Haemophilus, Neissena, Yersinia, Pseudomonas, Chlamydia, Bordetella, Treponema, Stenotrophomonas, Acinetobacter, Enterobacter, Klebsiella, Proteus, Serratia, Citrobacter, Enterococcus, Legionella, Mycoplasma, Chlamydophila, Moraxella, Morganella, and other human pathogens encountered in medical practice. Included in the genera are various species. For example, Klebsiella includes, but is not limited to, Klebsiella pneumoniae, Klebsiella ozaenae, Klebsiella rhinoscleromatis, Klebsiella oxytoca, Klebsiella planticola, Klebsiella terrigena, and Klebsiella ornithinolytica. Examples of viruses include viroids.


Similarly, microorganisms may comprise fungi selected from genera such as Candida, Aspergillus, and other human pathogens encountered in medical practice. Viruses can be, but are not limited to, orthomyxoviruses (e.g., influenza virus), paramyxoviruses (e.g., respiratory syncytial virus, mumps virus, measles virus), adenoviruses, rhinoviruses, coronaviruses, reoviruses, togaviruses (e.g., rubella virus), parvoviruses, poxviruses (e.g., variola virus, vaccinia virus), enteroviruses (e.g., poliovirus, coxsackievirus), hepatitis viruses (including hepatitis A, B, and C), herpesviruses (e.g., Herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-B an virus), rotaviruses, Norwalk viruses, hantavirus, arenavirus, rhabdovirus (e.g., rabies virus), retroviruses (including HIV, HTLVI and II), papovaviruses (e.g., papillomavirus), polyomaviruses, picornaviruses, and the like.


The methods and systems described herein can be used to identify host cells harboring viruses. The cells are first purified, and subsequently the cells are manipulated to either produce viruses, or to identify nucleic acids in the cells.


The sample can be obtained from any number of sources, including, but not limited to, bodily fluids (including, but not limited to, blood, urine, serum, lymph, saliva, anal and vaginal secretions, perspiration, peritoneal fluid, pleural fluid, effusions, ascites, and purulent secretions, lavage fluids, drained fluids, brush cytology specimens, biopsy tissue, explanted medical devices, infected catheters, pus, biofilms and semen) of virtually any organism, including mammalian samples and human samples, as well as environmental samples (including, but not limited to, air, agricultural, water and soil samples). In addition, samples can be taken from food processing, which can include both input samples (e.g., grains, milk or animal carcasses), samples in intermediate steps of processing, as well as finished food ready for the consumer. The method can be used for veterinary applications. The methods can be also used for the analysis of milk in the diagnosis and treatment of mastitis, and the analysis of respiratory samples for the diagnosis of bovine respiratory disease. Furthermore, the methods provide for the rapid detection of the presence of potential biological warfare agents in a sample.


Samples can range from less than a milliliter to up to a liter for certain respiratory lavage fluids, and can further range in bacterial concentration from less than one bacterium to greater than 109 bacteria per milliliter. Furthermore, the sample can be present in blood, urine, sputum, lavage fluid or other medium. The sample can be concentrated prior to using the described methods for purifying cells and/or viruses from the sample. Sample concentration both concentrates the sample so that bacteria that are present in small numbers can all be effectively introduced into the system and adequately sampled, as well as so the background liquid medium can be normalized, or in some cases eliminated or reduced, to have consistent properties upon introduction to the system. Sample concentration can be performed by centrifugation, combining samples, removing solvents, and the like. It should be noted, however, that certain samples provided in the description can be used without concentration or other modification.


The rapid detection of various cells and/or viruses is useful for a patient suffering from various diseases and disorders. For example, pneumonia can result from a variety of causes, including infection with bacteria, viruses, fungi, or parasites, as well as chemical or physical injury to the lungs. However, some samples of cells and/or viruses contain contaminants that interfere with their detection. Purification of a microorganism (or virus or other cell), and detection of the type and amount of a microorganism (or virus or other cell) present in a sample, are helpful to diagnose and treat a patient effectively.


In other embodiments, the cells are selectively lysed. For example in the case of intracellular targets, the mammalian cells can be lysed, releasing intracellular microorganisms prior to, during, or after the purification described herein.


Contaminants


Contaminants are removed from the sample into the medium. Contaminants that can be removed include ionic species, including, but not limited to, mono or divalent cations and anions, released intracellular materials, phospholipids, extracellular proteins, mucins, pulmonary surfactants, mucus plugs, pus, glycoproteins, and nucleic acids. Removing contaminants avoids other time intensive preparation steps such as vortexing and centrifugation. In various aspects, the removed contaminants interfere with cells and/or virus surface immobilization, detection, and imaging. Cells and/or viruses remain in the well, and can be recovered. In certain aspects of the purification methods, certain components, such as cellular membrane fragments and larger cellular fragments, are not removed from the sample.


Medium


Organogels, xerogels, and aerogels may also be utilized as the medium. Aerogels include, but are not limited to, silica aerogel, carbon aerogels, alumina, cadmium, and selenide aerogels. Organic aerogels, such as SEAge1, are made of agar. Aerogels made of chalcogens such as sulfur, selenium, and other elements may also be of utility.


In various embodiments, the medium is a hydrogel. In some embodiments, hydrogels are a network of polymer chains that are hydrophilic. Hydrogels can be highly absorbent natural or synthetic polymers, and in some instances can contain over 99% water. In general, hydrogels are solid, yet porous media.


The concentration of the hydrogel affects the migration speed of the contaminants through the hydrogel. Increasing the concentration of the hydrogel decreases the pore size within the hydrogel. Additionally, contaminants with smaller molecules move faster and migrate further than contaminants with larger molecules.


The charge of the hydrogel also affects the migration speed of the contaminants through the hydrogel. Each contaminant molecule migrates to the electrode that carries a charge opposite of that of the contaminant molecule. Most biological materials have a net negative surface charge. Some have a net positive charge if the material has an excess of amines or other positively-charge moieties exposed to the surface. The charge is considered neutral if it is a balance of positive and negative, or uncharged, such as complexes coated with neutral materials that envelope and screen charged materials within. The uncharged material will migrate in the direction of electro-osmotic flow, if present.


The pH of the hydrogel also affects the migration speed of the contaminants and the targets. In some embodiments, the pH is selected to enhance mobility of the contaminants relative to the cells and/or viruses. In some embodiments, a pH may be selected such that the cells and/or viruses are substantially near the isoelectric point, minimizing the cells' and/or viruses' mobility relative to the contaminants. In other embodiments, the pH may be selected to be substantially different from the isoelectric point such that the direction of the cells' and/or viruses' mobility is reversed relative to the contaminants.


In some embodiments, a medium contains nutrients that promote the viability of the cells and/or viruses.


Media used in the systems described can separate contaminant molecules based on both their size and their charge.


The hydrogel's porosity is directly related to the concentration of agarose in the medium. Various levels of effective viscosity can be selected, depending on the experimental objectives.


Examples of hydrogels are alginates, as disclosed in Gadkari, 2007, “Optimal hydrogels for fast and safe delivery of bioactive compounds”, Thesis of Drexel University; ethyl-vinyl-acetate copolymer as disclosed in U.S. Pat. No. 3,854,480; esters of hydantoic acid as disclosed in U.S. Pat. No. 3,792,081, olefin saturated polyester 500-8000, polyethylene glycol (PEG) 200-1500, ethyl-vinyl-acetate copolymer 20-40% VA (20-30K), chlorinated polyethylene 25-45% Cl— (20-30K), ethyl-ethylacrylate copolymer 20-40% EA (20-30K), and ethylene vinyl chloride copolymer 25-45% Cl— (20-30K) as disclosed in U.S. Pat. No. 3,938,515; methyl-methacrylate copolymer and glyceryl-methyacrylate copolymer as disclosed in U.S. Pat. No. 3,957,362; ethylene-vinyl-actetate copolymer 4-80% VA (20-30K) as disclosed in U.S. Pat. No. 4,069,307; polysiloxanes as disclosed in U.S. Pat. No. 4,136,250; hydrophilic dihydroxyalkyl acrylate and insoluble copolymer as disclosed in U.S. Pat. No. 4,267,295; cellulose triacetate as disclosed in U.S. Pat. No. 4,220,152; acrylamide, vinylpyrrolidone, and polyethyleneoxide diol as disclosed in U.S. Pat. No. 4,423,099; poly-amino acid homopolymers and copolymers as disclosed in U.S. Pat. No. 4,351,337; poly-glutamic acid ethyl-glutamate copolymer (5-50% GA, 80-500 KDa) as disclosed in U.S. Pat. No. 4,450,150; polyoxyethlyene-polyoxypropylene copolymer thermoset as disclosed in U.S. Pat. No. 4,478,822; vinyl cross-linked copolymers of insoluble and soluble monoolefinic esters as disclosed in U.S. Pat. No. 4,548,990; copolymers with N-vinyl-2-pyrrolidone and methacrylates as disclosed in U.S. Pat. No. 4,693,884; polyanhydride as disclosed in U.S. Pat. No. 4,657,543; copolymer of poly(alkylene oxide) and cyclic ester of alpha hydroxy acid (glycolide) as disclosed in U.S. Pat. No. 4,882,168; polyacrylonitrile-nitric acid copolymer as disclosed in U.S. Pat. No. 5,218,039; N-morpholinoethyl methacrylate and 2-hydroxyethyl methacrylate copolymer as disclosed in U.S. Pat. No. 4,857,313; crosslinked copolymers of vinyl pyrrolidone and allylamine as disclosed in U.S. Pat. No. 4,772,484; water soluble polyacetals having molecular weights from about 5,000-30,000 as disclosed in U.S. Pat. No. 4,713,441; thermoplastic hydrogels of polyvinyl pyrrolidone (PVP) and polyvinyl acetate (PVA), and gelatin as disclosed in U.S. Pat. No. 5,002,792; alginic acid with Ca++, Ba++ or Zn++, pectic acid with Ca++, Ba++ or Zn++, hyaluronic acid with Ca++, Ba++ or Zn++, polyglucuronic acid with Ca++, Ba++ or Zn++, polymanuronic acid with Ca++, Ba++ or Zn++, polygalacturonic acid with Ca++, Ba++ or Zn++, polyarabinic acid with Ca++, Ba++ or Zn++, and kappa-carrageenan with Ca++, Ba++ or Zn++, as disclosed in U.S. Pat. No. 5,089,606; charged side-chain polyphosphazenes with Ca++ cross-linking as disclosed in U.S. Pat. No. 5,149,543; carboxymethylcellulose as disclosed in U.S. Pat. No. 5,208,037; agarose as disclosed in U.S. Pat. No. 3,961,628; polyacrylamide as disclosed in U.S. Pat. No. 6,391,937; pluronic 127, N-isopropylacrylamide (NiPAM); and blends (block co-polymer, etc.) of all the above listed hydrogels.


Agarose is a linear polymer, made up of the repeating monomeric unit of agarobiose. Agarobiose is a disaccharide made up of D-galactose and 3,6-anhydro-L-galactopyranose. Agarose pectin or sulfonated agarose can be used as the hydrogel. Agarose can be obtained from Lonza (Rockland, Me.) under the brand name SeaKem™. In certain embodiments, the concentration of the agarose gel for effectively removing contaminants is from 0.1-2.0% w/v.


Purified agarose hydrogels may be purchased for use in the described method. An example of a commercial purified hydrogel can be obtained from Invitrogen (Carlsbad, Calif.) under the brand name E-Gel® EX Starter.


Polyacrylamide is a polymer (—CH2CHCONH2—) formed from acrylamide subunits. It can be synthesized as a simple linear-chain structure or cross-linked, typically using N,N′-methylenebisacrylamide. In the cross-linked form, polyacrylamide is highly water-absorbent, forming a soft gel. Polyacrylamide can be obtained from BioRad (Hercules, Calif.).


Purified polyacrylamide hydrogels may be purchased for use in the described method. An example of a commercial purified hydrogel can be obtained from BioRad (Hercules, Calif.).


Preconditioning of a medium can be performed. Preconditioning of a medium is often done to remove impurities found in the medium. For example, providing a potential across a hydrogel helps mobile impurities to migrate outside of the hydrogel. The potential can be, for example, 50V, 75V, 100V, 150V, 200V, 250V, 300V, 350V, 400V or 500V. In various embodiments, the potential can be provided for a period of time, such as at least 2 minutes, at least 5 minutes, at least 10 minutes, at least 15 minutes, at least 30 minutes, at least 45 minutes, at least 60 minutes, at least 120 minutes, or at least 180 minutes.


In various embodiments, the medium can be a filter. Examples of filters include those available from Pall Corporation (Port Washington, N.Y.), such as hydrophilic polypropylene, ahydrophilic, low binding material with pore sizes of 0.2 μm and 0.45 μm; polytetrafluoroethylene (PTFE), a hydrophobic, high binding material with pore sizes of 0.2 μm, 0.45 μm, 1 μm, 2 μm and 3 μm; glass fiber, a hydrophilic, moderate binding material with a pore size of 1 μm; nylon, a hydrophilic, low binding material with pore sizes of 0.2 μm and 0.45 μm; polyvinylidene fluoride (PVDF), a hydrophilic, low binding material with pore sizes of 0.2 μm and 0.45 μm; PES (Supor®), a hydrophilic, low binding material with pore sizes of 0.1 μm, 0.2 μm, 0.45 μm, and 0.8 μm; vinyl/acrylic copolymer, a hydrophobic material that may be used for air sampling and has pore sizes of 0.45 μm and 0.8 μm; polyvinyl chloride (PVC), which may also be used for air sampling and has pore sizes of 5 μm; hydrophilic mixed cellulose esters, a high binding material with a pore size of 0.45 μm; hydrophilic acrylic copolymer, which may be used as a pre-filter on a support and has pore sizes of 0.2 μm, 0.45 μm, 0.8 μm, 1.2 μm, 3 μm, and 5 μm; and nitrocellulose, a high binding material with a pore size of 0.2 μm. Examples of filters available from Millipore (Billerica, Mass.) include PTFE (LCR), a hydrophilic, moderate binding material with pore sizes of 0.2 μm and 0.45 μm; PVDF (Durapore™), a hydrophilic, low binding material with pore sizes of 0.2 μm and 0.45 μm; PTFE (Fluoropore™), a hydrophilic, low binding material with pore sizes of 0.2 μm and 0.45 μm; nylon, a hydrophilic, low binding material with pore sizes of 0.2 μm and 0.45 μm; glass fiber, a hydrophilic, moderate binding material with a pore size of 1 μm; and hydrophilic mixed cellulose esters, a high binding material with exemplary pore sizes of 0.2 μm, 0.45 μm, and 0.8 μm. Filters can have pore sizes of greater than or equal to about 0.01 μm, 0.05 μm, or 0.1 μm, 0.2 μm, 0.4 μm, 0.6 μm, 0.8 μm, 1.0 μm, 1.5 μm, 2.0 μm, 2.5 μm, 3.0 μm, 4.0 μm, or 5.0 μm. Filters can have pore sizes of less than or equal to about 5.0 μm, 4.0 μm, 3.0 μm, 2.5 μm, 2.0 μm, 1.5 μm, 1.0 μm, 0.8 μm, 0.6 μm, 0.4 μm, 0.2 μm, 0.05 μm, or 0.01 μm.


In various embodiments the method includes adding a chemical agent to the medium to increase the permeability of the medium and/or increase the ability of the contaminant to enter the medium.


Examples of chemical agents include reducing agents, including, but not limited to, dithiothreitol (DTT), tris(2-carboxyethyl)phosphine (TCEP), and mercaptoethanol reducing agents; denaturing agent using surfactants, including, but not limited to, sodium lauryl sulfates, non-ionic surfactants such as Triton X-100, Tween-20, or chaotropic agents, including, but not limited to, urea, thiourea, or guanidinium chloride; chelating agents that can coordinate molecules such as calcium, magnesium, and other divalent and trivalent ions (including metal ions), including ethylenediaminetetraacetic acid (EDTA) and ethylene glycol tetraacetic acid (EGTA); cleavage agents including proteases, nucleases, glyconases, lipases; and excipients such as polyethylene glycol. In some embodiments a combination of one or more chemical agents can be utilized.


Viscous gels include cellulose ethers (such as hydroxylethyl cellulose or Methocel™ (Dow (Midland, Mich.)) and soluble polymer viscosity modifiers (such as polyethylene glycol, polyvinylpyrrolidone, dextrans, pluronic surfactants, and alginates). In a viscous gel, the pore size is not defined. The separation is based on retarded flow of the cells in the viscous medium.


In some embodiments, agents can be added to or used to treat the medium to control electroosmotic flow. In some embodiments, it may be desirable to increase or decrease electroosmotic flow.


Sample Mixing


To analyze a representative sample, the sample should be substantially uniform. In some embodiments, the homogenization of a sample can be done by a sample mixing or stirring step. Mixing the sample acts to re-suspend any caked material formed on the walls of the well.


In various embodiments, the method includes mixing a sample using a pipette tip. See, for example, the pipette tip 228 in FIG. 2A. The sample is passed through the narrow opening of the pipette to shear and homogenize the sample.


Buffer Solutions


In various embodiments, the method includes placing a buffer in contact with the medium.


In some embodiments, the mixing parameters of the buffer are designed to maximize the removal of debris and non-target material.


In some embodiments, the buffer can be replenished to prevent accumulation of undesirable electrophoresis products. For example, undesirable effects pH gradients generated at the cathode and anode and in proximity to the sample can be substantially minimized by buffer replenishment or replacement, potentially using continuous flow.


In various embodiments, electrophoretic buffers utilize pairs of redox mediators. In certain embodiments, these redox mediators facilitate low voltage electrophoresis that permits cell viability to be maintained. These redox mediators may also enable the use of electrode materials that have limited utility in high voltage electrophoresis (for example, indium tin oxide, “ITO” electrodes). In addition, these redox mediators find use in “closed systems” (i.e., systems not open to the atmosphere). In closed systems, bubble formation and generation of other reactive species during the electrophoresis step, which can cause a number of problems, is prevented, and closed systems also help to prevent the exposure of the technician to potentially infectious samples, as well as reducing problems associated with discarding biological samples


In some embodiments, the buffer is placed in a reservoir in contact with the medium. In various embodiments, the medium is not submerged in the buffer.


Buffers include, for example, various electrophoresis buffers including zwitterionic buffers, neutral buffers such as phosphate-buffered saline (PBS), lower or higher pH buffers, and hypotonic or hypertonic buffers. In some embodiments, borate and other selected ions and counter-ions are included to facilitate effective electrophoresis.


In some embodiments, the buffer solution includes histidine and tris(hydroxymethyl)aminomethane. Histidine has low conductivity. Tris(hydroxymethyl)aminomethane has some conductivity but has low mobility. Histidine has pKa values close to physiological values providing adequate buffering capacity. Tris(hydroxymethyl)aminomethane can be obtained from Sigma-Aldrich (St. Louis, Mo.) as Trizma® base (Sigma, T1503).


In some embodiments, the sample (in 150 mM NaCl) is desalted to remove cationic and anionic species that may interfere with subsequent analysis. In some embodiments, desalting allows successful concentration and capture of the microorganism.


Electrophoretic mobility can be buffer dependent due to zeta potential variability with salt concentration, valency of salts present in the buffer, and the pH of the buffer. Bacteria can lose charge as the concentration of salt increases or as the pH is lowered below a certain pH, for example, pH 5.0. Divalent and trivalent salts are more effective quenchers than monovalent salts. For example, CaCl2 is more effective than NaCl to quench a charge. Certain agents such as chelators, including, but not limited to, ethylenediaminetetraacetic acid (EDTA) and ethylene glycol tetraacetic acid (EGTA), both available from Sigma-Aldrich, can be used to control the concentration of charged species in the sample.


Wells


As shown in FIG. 2A, one or a plurality of wells can be formed in the medium. The wells are molded into the gel. For example, a custom well-forming comb can be used to create the appropriate well shape. Wells include side-walls that can be substantially vertical or diagonal. In various embodiments, the method includes wells that are non-rectangular shaped. In various embodiments, the wells are substantially chamfered to eliminate sharp edges in the well, enhancing target recovery. In some embodiments, the wells can hold various sample sizes. In various embodiments, the wells can hold from 10 μL to 500 μL. In some embodiments the wells are 5 to 250 mm wide. Multiple wells can be used for a sample. As illustrated in FIG. 8, a well 822 in medium 820 may be circular, surrounding an electrode such as cathode 804, and the counter electrodes may surround the well, such as the illustrated anode ring 802. In a circular well configuration, a sample placed in well 822 surrounds the cathode 804. In such an embodiment, a run buffer sheath may flow over cathode 804 to remove electrode byproducts during electrophoresis.



FIG. 3 depicts a side view of an embodiment of a custom well-forming comb 300. A comb body 302 has a plurality of well-forming teeth 304 connected to the comb body 302 by one edge 306. The sides of the teeth 308 form the side-walls of the non-rectangular shaped wells in a medium. In this embodiment the wells are triangular-shaped. The comb 300 is sized and shaped to fit the medium in a cassette, such as the cassette shown in FIG. 2A. In the illustrated embodiment, the comb 300 has six well-forming teeth 304, but could have more or less teeth depending on the size of the cassette.


In a rectangular or square bottomed well, sample solution can wick up the walls of the well. In a triangular shaped well, the sample solution does not tend as strongly to wick up the walls, making it easier to remove the microorganism from the well. In some embodiments, the triangular shaped well is narrowest at the bottom and widest at the top of the well. The well-forming teeth 304 shown in FIG. 3 create a pattern of triangular shaped wells in the medium. In other embodiments, the wells may be round-bottomed wells.


The samples can have high solids (e.g., from 1%-50% weight/volume of solid components). Minimizing the well width minimizes the caking of the solids on the well walls. In some embodiments, the well is 0.0025 inches wide at the widest point.


Chambers


In various embodiments, the method uses a system 900 wherein one or a plurality of chambers 953 can be formed in a medium 920. The chambers 953 are molded into the gel 920 and have an inlet and outlet port (954 and 955) as shown in FIG. 9. Inlet and outlet ports 954 and 955 are connected by tubing 956 for recirculating a sample through a chamber 953, such as by a peristaltic pump. The chambers may be submerged or partially submerged in buffer, and electrical potential is applied to the system orthogonally to the direction of the recirculating flow of sample.


Electrodes


In various embodiments of the method, an electrode or a plurality of electrodes may be contained within the well or chamber. Additionally, in various embodiments, the electrode or plurality of electrodes may be in contact with the medium or separated a distance from the medium. The electrode or plurality of electrodes may be connected to the medium using salt bridges, buffer, redox mediators, or other conductive charge transfer methods used by those skilled in the art or familiar with techniques used in applications for establishing faradaic current. In some embodiments the electrodes are in physical contact with the chamber walls.


In various embodiments, conductive materials may be utilized to distort the electric field resulting in localized concentration of cells and/or viruses. Electric field distortion may utilize material conductivity differences to accomplish the said localization.


Immobilization of the Cells and/or Viruses


In various embodiments, the method includes immobilizing the microorganism. Cells and/or viruses are immobilized by various filters that exclude the targets (microorganism) from penetrating, for example, tube walls, microchannels (horizontal or vertical), or any geometry that uses a capture surface (specific or nonspecific), mazes, fluidic dead space (eddy cul-de-sacs), and microwells of approximate cellular scale.


Detection Surface


In some embodiments, the method includes immobilization of cells and/or viruses on a positively charged surface. For example, cells and/or viruses can be immobilized by a positively charged detection surface. In other embodiments, the cells and/or viruses may be immobilized by embedding in the medium.


Detection surfaces are disclosed in, for example, U.S. Pat. No. 6,844,028, incorporated by reference herein in its entirety. Detection surfaces can include those coated with poly-L-lysine, polyethylenimine, or other cationic polymers. Additionally, detection surfaces can include hydrophobic surface coatings.


After the contaminants are removed from the sample by the medium, the microorganism can be detected by a system. In some embodiments, the system is an optical sensing system. In some embodiments, the system is a microscope.


In some embodiments, the system is an automated system.


In various embodiments, the sequential or simultaneous use of a plurality of electrophoresis electrodes allows multidimensional electrophoresis, i.e., the solution may be targeted, “mixed,” or “stirred” in the vicinity of a detection surface to further increase the kinetics of binding. For example, polarities can be reversed to allow cells and/or viruses that may not have bound to the detection surface to travel back “over” the surface, resulting in increased binding. Also, electrodes may be located and field polarity switched according to a programmed sequence so as to provide agitation in two dimensions of a plane, or in three dimensions.


Detection of the Microorganism


In various embodiments, the method includes detection of the microorganism. In general, biosensor devices are designed to fit into a detection unit, and generally utilize a number of components, which can either be “on-chip” (e.g., part of a biosensor cartridge) or “off-chip” (where some of the components are part of separate device or devices into which the biosensor cartridge fits). These components include, but are not limited to, one or a plurality (e.g., an array) of detection surface(s), concentration modules (which, as outlined herein, frequently are configured with the detection surface(s)), detection modules (again, frequently configured with the detection surface(s)), input and output ports, channels, pumps, mixers, valves, heaters, fluid reservoirs (including sample reservoirs, reagent reservoirs, and buffer reservoirs), concentration controllers (e.g., in the case of electrophoresis, electrical controllers), and data collection and analysis (e.g., computer) components.


An example of a microorganism diagnostic system is described in U.S. patent application Ser. No. 10/888,828 filed Jul. 8, 2004, issued as U.S. Pat. No. 7,687,239, and U.S. application Ser. No. 11/303,803, filed Dec. 16, 2005, issued as U.S. Pat. No. 7,341,841, both of which are incorporated herein by reference in their entirety.


Low levels of cells and/or viruses can be detected with this method. Cells can be measure in terms of cells per mL, colony forming units (CFU, or units) per mL for fungi and/or bacterial microorganisms, and viruses can be measured in particles per mL or plaque forming units per mL (PFU). Levels of cells and/or viruses are described in units per volume, typically per mL volume. Those skilled in the art understand the specific units are typically reported as appropriate for a given target. For exemplary purposes, the concentration ranges below are reported in generic units per mL. For example, levels of 0.1 to 1×108 units/mL can be detected. In various embodiments, cells and/or viruses of levels less than 5×108 units/mL, 3×108 units/mL, 1×108 units/mL, 0.8×108 units/mL, 0.6×108 units/mL, 0.4×108 units/mL, 0.2×108 units/mL, or 0.1×108 units/mL, can be detected.


EXAMPLES

The following examples are provided for illustration purposes and are not intended to limit scope. Other variants will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims.


The example described below anticipates a wide range of specimen variability, first homogenizing the specimen, then sampling the specimen, and then purifying the sample to remove debris and other interfering materials by placing the sample in a medium containing a well and applying a potential laterally across the medium to retain cells and pass contaminants into the medium.


Example 1. Purification of Bacteria Cells from Respiratory Specimens

Gel Preparation


10 grams of agarose powder (SeaKem, LE Agarose) was mixed with 1 L of buffered solution containing 100 mM histidine (Sigma, H8000) and 2.5 mM Trizma® base (Sigma, T1503). The final concentration of agarose slurry was 1.0% (w/v). The solution was boiled to melt the agarose powder and the molten agarose was stored in liquid form at 40° C. until use.


Gel Casting


Those familiar in the art of gel slab electrophoresis recognize that solid inserts or combs are routinely used to create a void volume in a gel slab that is later utilized for sample loading. Gel electrophoresis combs are generally nominally 1-2 mm thick, capable of holding nominally 100 μL of sample volume. In this example, a custom equilateral V-shaped well was used. The well had sides 1 cm long and a thickness of nominally 0.6 mm (0.025″). The comb was inserted into a gel box container (E-C Apparatus, EC 250-90) and the box filled with the molten agarose submerging a portion of the comb. The agarose was allowed to cool to room temperature forming an agarose gel. The comb was removed from the solidified agarose and the void volume of the comb formed a well in the material. The V-shaped well enabled facile recovery of the sample volume from the well, described in further detail below.


Pretreatment of the Agarose Gel Medium


The gel box containing the agarose gel medium having triangular wells was placed in an electrophoresis apparatus and then submerged in a run buffer containing 100 mM histidine and 2.5 mM Trizma® base. A 250 volt potential was applied for 1 hr. The applied potential yielded 22 mA of current. The pretreated gels were removed from the electrophoresis apparatus and transferred to a closed container and stored submerged in fresh run buffer until use.


Specimen Homogenization


A remnant specimen having a known level of bacteria was homogenized by pouring into a syringe connected to 0.02″ (0.5 mm) inner diameter PEEK tubing and forcing through the PEEK tubing 10 times at a flow rate of approximately 0.1 mL/sec to liquefy the specimens. The specimen was then filtered through 5 μm track etch polycarbonate filters (SPI Pore, E5013-MB). A 1 mL sample aliquot of the specimen was processed as described below. An aliquot of the specimen was also reserved as a control.


A control or a known clinical sample (e.g., with a known concentration of bacteria) can be compared to the unknown sample.


Assessment of the Sample


The sample was diluted to a final nominal bacterial concentration of 1.5×103 CFU/mL. 50 μL of the diluted sample was plated in triplicate on Mueller Hinton Agar (MHA) and placed in the incubator overnight. The number of colonies counted on the overnight incubated plates divided by the plated volume and multiplied by dilution factor yielded the actual number of input Klebsiella oxytoca bacteria in CFU/mL.


The sample was diluted 10-fold and the optical density read was acquired at 625 nm to assess the amount of particulate debris in the sample.


Sample Loading


The pretreated gels were placed in the gel box and apparatus, patted dry, and excess liquid was removed from the triangular wells using 0.2 mm thick flat capillary plastic pipette tips (Fisher 07-200-519). The well was filled with a 20 μL sample of the homogenized specimen.


Sample Treatment


Histidine/Tris run buffer was added to the apparatus so that the liquid level was below the top of the gel slab. The sample was electrophoresed for 5 minutes at 250 volts and the samples were hydrodynamically sheared by pipetting the sample volume up and down 5× using a capillary pipette tip. The samples were electrophoresed again for 5 minutes at 250 volts and the samples then hydrodynamically sheared by pipetting the sample volume up and down 5× using a capillary pipette tip.


Post-Treatment Assessment of Spiked Sample


The treated sample was diluted to a final concentration of 1.5×103 CFU/mL. 50 μL of the diluted sample was plated in triplicate on Mueller Hinton Agar (MHA) and place in the incubator overnight. The number of colonies counted on the overnight incubated plates divided by the plated volume and multiplied by dilution factor yielded the actual number of Klebsiella oxytoca bacteria recovered in CFU/mL.


The treated sample was diluted 10-fold and then the optical density read was acquired at 625 nm to assess the amount of particulate debris remaining in the sample.


Results



















Pre-Treatment
Post-Treatment





Optical Density
Optical Density
Fold




(OD)
(OD)
Cleanup









MEDIA
0.2841
0.065
4.35



METHOD














Electrode Configuration and Circuit Details


The 20 μL of recovered sample volume was diluted with 40 μL of 10 mM ascorbic acid and then introduced into a flow cell (described below) for electrokinetic concentration.


For comparison purposes, a 20 μL of a non-treated sample was diluted with 40 μL of 10 mM ascorbic acid and then introduced into a flow cell (described below) for electrokinetic concentration.


Flow Cell Construction



FIG. 4A is a perspective view of a multiple flow cell laminate flow cell assembly 400, and FIG. 4B is a single flow cell cutaway view with corresponding electrode and circuit details. Flow cells were assembled using a three layer die-cut laminate flow cell assembly 450 (DLE, Oceanside, Calif.), sandwiched between an indium tin oxide (ITO) coated glass slide flow cell floor 451 (Delta Technology, Stillwater, Minn.) and an ITO coated 5 mil polyester (ITO PET) plastic flow cell ceiling 452 (Sheldahl, Northfield, Minn.) forming a fluidic flow cell chamber. The laminate flow cell assembly contained 32 separate channels 453, each having 1.78 mm width×0.30 mm height×11.28 mm length, with 1.78 mm diameter fluidic inlet and outlet ports (454 and 455, respectively) to interface with plastic pipette tips for fluid exchanges using manual pipettors. The transparent top and bottom electrodes enabled microscope imaging.


Bacteria 401 suspended in redox active EKB were contacted with uniform transparent electrodes constructed from transparent ITO coated glass (Delta Technologies, Stillwater, Minn.) or polyester film (Sheldahl, Northfield, Minn.). A potential was applied to the conductive ITO surfaces completing the circuit, establishing a faradaic current and an electric field between the electrodes and enabling bacterial electrokinetic concentration (EKC) and surface immobilization, as illustrated in FIG. 4B.


Bacterial Suspension and Surface Concentration Experiments


Studies were performed by loading the flow cells with samples, with the power supply turned off, and then inserting the flow cells onto the microscope stage. The microscope acquired images at the bottom flow cell surface during subsequent steps. The power supply was connected and cells electrokinetically concentrated to the flow cell's bottom surface by application of a 1.4V DC fixed potential. The top electrode (flow cell ceiling) was connected to the negative power supply terminal, and the bottom electrode (flow cell floor) was connected to the positive terminal. The applied potential resulted in complete bacterial concentration in less than 3 minutes. After 300 seconds, a −1.0 V DC fixed potential was applied for an additional 60 seconds to measure the degree of irreversible binding of the sample debris and bacteria on the flow cell floor. The digital microscope acquired images every 3-7 seconds during concentration.


Digital Microscopy Setup


An Olympus IX-71 inverted microscope equipped with a 12-bit, 1200×1600 pixel array monochrome CCD digital camera (MicroFire, Leeds Precision Instruments, Minneapolis, Minn.) was used for image acquisition. The transmitted illumination cone, created with an IX-PH3 annular ring placed in a 0.55 NA transmitted light condenser, was 33.4° from the normal to the microscope's focal plane. The illumination cone, after refraction through the flow cell's air-glass-ITO-liquid interfaces (described below), resulted in a 24.5° forward scatter angle-of-incidence relative to the focal plane normal. The forward scatter angle-of-incidence relative to the flow cell's air-plastic-ITO-liquid interfaces was not calculated. In all formats, a dark image was obtained in the absence of scatterers, as the illumination cone passed outside the 20×, 0.4 NA microscope objective's (LCPlanFl Olympus, Leeds Precision Instruments) imaging cone. The presence of scatterers resulted in the appearance of bright objects on a dark image background (dark-field image for objects within the focal depth). The system field-of-view was 444×592 μm with corresponding 0.37 μm pixel resolution. The imaging system's depth-of-focus and image depth were 5.8 μm and 3.8 mm respectively. Constant camera exposure and gain settings were maintained when relative intensity comparisons were performed, as in the case of growth experiments described below.


Accumulation Time Results



FIG. 5 is a graph showing results of accumulated objects over time for treated compared to non-treated samples. The non-treated sample data is expected data.


The objects are solid material, such as cells, viruses, and cellular debris, that are immobilized on a sample surface. FIG. 5 shows that material concentrates, and then adheres to, the surface. Subsequent processes, such as measuring the growth or growth rate, can be utilized to determine the number of viable cells, and additionally probing the material using receptor-ligand binding techniques, including, but not limited to, antibody recognition or nucleic acid hybridization methods can be used to measure the abundance of microorganisms present.



FIGS. 6A, 6B and 6C depict microscopic images of non-treated samples at initial time, time of 300 seconds, and time of 360 seconds, respectively. The surface accumulation rate is low. As shown in FIGS. 6A, 6B and 6C, poor surface retention of the objects occurs when samples are not treated.



FIGS. 7A, 7B and 7C depict microscopic images of treated samples at initial time, time of 300 seconds, and time of 360 seconds, respectively. The treated sample surface accumulates all objects, as evidenced by a plateau occurring in less than 3 minutes. As shown in FIGS. 7A, 7B and 7C, the objects were irreversibly bound to the surface, as evidenced by consistent accumulated counts during reverse electrophoresis.


Bacterial Growth


After cell immobilization, the flow cell was rinsed with 10 times the internal cell volume of 1/10th strength cation-adjusted Mueller-Hinton Broth (CAMHB) growth media (Difco, Sparks, Md.). 100 μL of liquefied Mueller Hinton Agar (MHA) was loaded into the flow cell and then cooled to room temperature, solidifying into a hydrogel.


Time Lapse Imaging


Direct observation of bacterial growth was performed by inserting the disposable 32-channel flow cell assembly into a custom benchtop automated instrument that combined digital microscopy, motion control, and image analysis software. The system was enclosed in an incubator maintained at 35° C. The motorized microscope stage enabled automated XY translation, location logging, and memory with 10 μm repeatability. The system automatically focused and acquired surface images of adherent bacteria at programmed time intervals for multiple fields-of-view during an experiment. The system used the fiducial markings to autofocus and mechanically align (±1 pixel) the fields-of-view prior to image acquisition. Unless stated otherwise, a single field-of-view contained sufficient numbers of cells for analysis, and automated analysis routines counted the number of growing clones.


Growth Results


The number of growing clones observed using the digital microscope method was compared with the number of expected growing clones, assuming 100% yield and a 1 to 1 correlation between growing colonies on MHA plates, to calculate a digital microscopy method efficiency. The medium method was compared to an alternative medium method wherein the gel was submerged. A total efficiency was calculated by multiplying the treatment recovery and digital microscopy efficiency.




















Digital





Post Treatment
Microscopy
Total




Recovery
EFF
EFF





















Control-No Prep
100% 
12%
12%



Medium Method
82%
90%
74%



Submerged Medium






Method
43%
100% 
43%











The total efficiency for the medium method was highest when the gel slab was not submerged.


All directional references (e.g., proximal, distal, upper, lower, upward, downward, left, right, lateral, front, back, top, bottom, above, below, vertical, horizontal, clockwise, and counterclockwise) are only used for identification purposes to aid the reader's understanding of the present invention, and do not create limitations, particularly as to the position, orientation, or use of the invention. Connection references (e.g., attached, coupled, connected, and joined) are to be construed broadly and may include intermediate members between a collection of elements and relative movement between elements unless otherwise indicated. As such, connection references do not necessarily imply that two elements are directly connected and in fixed relation to each other. The exemplary drawings are for purposes of illustration only, and the dimensions, positions, order and relative sizes reflected in the drawings attached hereto may vary.


Numerous and varied other arrangements can be readily devised by those skilled in the art without departing from the spirit and scope of the description. Moreover, all statements herein reciting principles, aspects and embodiments, as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents as well as equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. All references cited herein are incorporated by reference in their entirety.

Claims
  • 1. A method of purifying at least one of cells and viruses in a sample, comprising: adding a sample containing contaminants and at least one of cells and viruses to a well disposed in a porous medium, wherein the porous medium comprises pores smaller than the at least one of cells and viruses, thereby preventing the at least one of cells and viruses from entering the medium;applying an electrical potential across the medium to cause the contaminants to enter the porous medium through one or more walls of the well while retaining the at least one of the cells and viruses in the well; andremoving the at least one of the cells and viruses from the well.
  • 2. The method of claim 1, wherein the cells are bacteria.
  • 3. The method of claim 1, wherein the sample comprises cerebrospinal fluid.
  • 4. The method of claim 1, wherein the sample comprises blood or plasma.
  • 5. The method of claim 1, wherein the sample comprises a respiratory specimen.
  • 6. The method of claim 1, wherein the sample comprises urine.
  • 7. The method of claim 1, wherein the porous medium comprises at least one of a filter or a hydrogel.
  • 8. The method of claim 7, wherein the hydrogel comprises at least one of polyacrylamide or agarose.
  • 9. The method of claim 1, further comprising placing a buffer in contact with the porous medium.
  • 10. The method of claim 9, wherein the buffer is replenished prior to removing the at least one of cells and viruses from the well.
  • 11. The method of claim 10, wherein the buffer comprises histidine and tris(hydroxymethyl)aminomethane.
  • 12. The method of claim 1, further comprising adding a chemical agent to the sample to increase a permeability of the porous medium to the contaminants.
  • 13. The method of claim 1, further comprising applying a tangential flow to the medium to remove non-permeable contaminants from the surface of the porous medium.
  • 14. The method of claim 1, further comprising concentrating in the well the at least one of cells and viruses.
  • 15. The method of claim 1, further comprising repeating the adding step and the applying step prior to removing the at least one of the cells and viruses from the well.
  • 16. The method of claim 1, further comprising mixing the sample.
  • 17. The method of claim 16, wherein the sample is mixed by at least one of stirring the sample, repeatedly passing the sample through a pipette tip, and repeatedly forcing the sample through tubing connected to a syringe.
  • 18. The method of claim 16, wherein the sample is mixed at least one of before application of the electrical potential, during application of the electrical potential, and after application of the electrical potential.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 14/004,145, filed Oct. 16, 2013, which is a U.S. National Phase filing under U.S.C. § 371 of PCT/US2012/028139, filed Mar. 7, 2012, and claims priority from U.S. Provisional Patent Application No. 61/449,824, filed Mar. 7, 2011, all of which are incorporated herein by reference in their entirety.

US Referenced Citations (414)
Number Name Date Kind
2666355 Trurnit Jan 1954 A
3493772 Daughters, II et al. Feb 1970 A
3532790 Greenberg et al. Oct 1970 A
3637313 Upatnieks Jan 1972 A
3792081 Higuchi et al. Feb 1974 A
3811036 Perry May 1974 A
3832532 Praglin et al. Aug 1974 A
3854480 Zaffaroni Dec 1974 A
3904293 Gee Sep 1975 A
3926564 Giaever Dec 1975 A
3935073 Waters Jan 1976 A
3938515 Leeper et al. Feb 1976 A
3957362 Mancini et al. May 1976 A
3961628 Arnold Jun 1976 A
4069307 Higuchi et al. Jan 1978 A
4070248 Schmidt Jan 1978 A
4076591 Heden Feb 1978 A
4136250 Mueller et al. Jan 1979 A
4199449 Slejko Apr 1980 A
4199499 Smithwick, Jr. et al. Apr 1980 A
4200493 Wilkins et al. Apr 1980 A
4220152 Dresback Sep 1980 A
4224439 Ayers et al. Sep 1980 A
4233847 Walker Nov 1980 A
4246343 Wilkins et al. Jan 1981 A
4259442 Gayral Mar 1981 A
4282287 Giese Aug 1981 A
4288543 Sielaff et al. Sep 1981 A
4313734 Leuvering Feb 1982 A
4325910 Jordan Apr 1982 A
4330440 Ayers et al. May 1982 A
4332476 Stenberg et al. Jun 1982 A
4351337 Sidman Sep 1982 A
4357142 Schall, Jr. et al. Nov 1982 A
4363634 Schall, Jr. Dec 1982 A
4383757 Phillips May 1983 A
4390343 Walter Jun 1983 A
4423099 Mueller et al. Dec 1983 A
4450150 Sidman May 1984 A
RE31712 Giese Oct 1984 E
4478822 Haslam et al. Oct 1984 A
4478914 Giese Oct 1984 A
4481137 Ohnishi et al. Nov 1984 A
4487839 Kamentsky Dec 1984 A
4500778 Kusaka et al. Feb 1985 A
4508832 Carter et al. Apr 1985 A
4509841 Sakai et al. Apr 1985 A
4521522 Lundstrom et al. Jun 1985 A
4537861 Elings et al. Aug 1985 A
4540881 Hayashi et al. Sep 1985 A
4548990 Mueller et al. Oct 1985 A
4558012 Nygren et al. Dec 1985 A
4588624 Nygren et al. May 1986 A
4613567 Yasoshima et al. Sep 1986 A
4626674 Oinoue Dec 1986 A
4643968 Weaver Feb 1987 A
4655595 Bjork et al. Apr 1987 A
4657543 Langer et al. Apr 1987 A
4661913 Wu et al. Apr 1987 A
4663296 Revillet et al. May 1987 A
4693884 Kleiner et al. Sep 1987 A
4693972 Mansour et al. Sep 1987 A
4713441 Heller et al. Dec 1987 A
4716123 Wood Dec 1987 A
4752567 De Brabander et al. Jun 1988 A
4764342 Kelln et al. Aug 1988 A
4772484 Kitchell et al. Sep 1988 A
4778758 Ericsson et al. Oct 1988 A
4805623 Jobsis Feb 1989 A
4814144 Edelmann et al. Mar 1989 A
4857313 Song et al. Aug 1989 A
4876208 Gustafson et al. Oct 1989 A
4877659 Vince Oct 1989 A
4882168 Casey et al. Nov 1989 A
4885077 Karakelle et al. Dec 1989 A
4933147 Hollar et al. Jun 1990 A
4959301 Weaver et al. Sep 1990 A
5002792 Vegoe Mar 1991 A
RE33581 Nicoli et al. Apr 1991 E
5017009 Schutt et al. May 1991 A
5066465 Kano et al. Nov 1991 A
5079144 Carr et al. Jan 1992 A
5079172 Hari et al. Jan 1992 A
5082630 Partin et al. Jan 1992 A
5089606 Cole et al. Feb 1992 A
5149543 Cohen et al. Sep 1992 A
5173164 Egen et al. Dec 1992 A
5196527 Ookuma et al. Mar 1993 A
5208037 Wright et al. May 1993 A
5218039 Stoy et al. Jun 1993 A
5239170 Hughlett Aug 1993 A
5240618 Caldwell et al. Aug 1993 A
5288611 Kohne Feb 1994 A
5314805 Haugland et al. May 1994 A
5329461 Allen et al. Jul 1994 A
5350697 Swope et al. Sep 1994 A
5405783 Pirrung et al. Apr 1995 A
5466416 Ghaed et al. Nov 1995 A
5468606 Bogart et al. Nov 1995 A
5488567 Allen et al. Jan 1996 A
5491097 Ribi et al. Feb 1996 A
5494829 Sandstrom et al. Feb 1996 A
5496701 Pollard-Knight Mar 1996 A
5556764 Sizto et al. Sep 1996 A
5578460 Ebersole et al. Nov 1996 A
5599668 Stimpson et al. Feb 1997 A
5604099 Erlich et al. Feb 1997 A
5622868 Clarke et al. Apr 1997 A
5623707 Kusaka Apr 1997 A
5648652 Sekiya et al. Jul 1997 A
5656432 Claverys et al. Aug 1997 A
5789173 Peck et al. Aug 1998 A
5792622 Botsford Aug 1998 A
5824494 Feldberg Oct 1998 A
5828716 Bisconte de Saint Julien Oct 1998 A
5843651 Stimpson et al. Dec 1998 A
5849486 Heller et al. Dec 1998 A
5863754 Bajard Jan 1999 A
5866345 Wilding et al. Feb 1999 A
5872013 Leunissen et al. Feb 1999 A
5888760 Godsey et al. Mar 1999 A
5922593 Livingston Jul 1999 A
5939291 Loewy et al. Aug 1999 A
5958704 Starzl et al. Sep 1999 A
5976821 Huston et al. Nov 1999 A
5981268 Kovacs et al. Nov 1999 A
5993634 Simpson et al. Nov 1999 A
6017696 Heller Jan 2000 A
6043048 Johnston et al. Mar 2000 A
6051380 Sosnowski et al. Apr 2000 A
6054270 Southern Apr 2000 A
6086824 Fanning et al. Jul 2000 A
6096272 Clark et al. Aug 2000 A
6099803 Ackley et al. Aug 2000 A
6101946 Martinsky Aug 2000 A
6103479 Taylor Aug 2000 A
6107054 Gibbs Aug 2000 A
6122599 Mehta Sep 2000 A
6136171 Frazier et al. Oct 2000 A
6143247 Sheppard, Jr. et al. Nov 2000 A
6153400 Matsumura et al. Nov 2000 A
6153416 Yuan Nov 2000 A
6169394 Frazier et al. Jan 2001 B1
6176620 Obara Jan 2001 B1
6214560 Yguerabide et al. Apr 2001 B1
6221592 Schwartz et al. Apr 2001 B1
6241894 Briggs et al. Jun 2001 B1
6242188 Dattagupta et al. Jun 2001 B1
6245508 Heller et al. Jun 2001 B1
6251615 Oberhardt Jun 2001 B1
6251616 Barbera-Guillem et al. Jun 2001 B1
6251624 Matsumura et al. Jun 2001 B1
6264825 Blackburn et al. Jul 2001 B1
6270953 Malcus-Vocanson et al. Aug 2001 B1
6274384 Starzl et al. Aug 2001 B1
6290839 Kayyem et al. Sep 2001 B1
6372895 Bentsen et al. Apr 2002 B1
6379897 Weidenhammer et al. Apr 2002 B1
6391264 Hammer et al. May 2002 B2
6391546 Karube et al. May 2002 B1
6391577 Mikkelsen et al. May 2002 B1
6391937 Beuhler et al. May 2002 B1
6395506 Pitner et al. May 2002 B1
6403367 Cheng et al. Jun 2002 B1
6416969 Matsumura et al. Jul 2002 B2
6432694 Malmqvist Aug 2002 B1
6437551 Krulevitch et al. Aug 2002 B1
6472166 Wardlaw et al. Oct 2002 B1
6472228 Wang et al. Oct 2002 B2
6548263 Kapur et al. Apr 2003 B1
6551841 Wilding et al. Apr 2003 B1
6565727 Shenderov May 2003 B1
6573088 Gemmell et al. Jun 2003 B2
6596532 Hyman et al. Jul 2003 B1
6605453 Ozkan et al. Aug 2003 B2
6607888 Schwartz et al. Aug 2003 B2
6611765 Boeufgras et al. Aug 2003 B2
6642682 Perkins et al. Nov 2003 B1
6696286 Halverson et al. Feb 2004 B1
6703819 Gascoyne Mar 2004 B2
6716620 Bashir et al. Apr 2004 B2
6809862 Behnsen et al. Oct 2004 B2
6841379 Matson Jan 2005 B2
6844028 Mao et al. Jan 2005 B2
6872545 Griner et al. Mar 2005 B2
6900030 Pitner et al. May 2005 B2
6951714 Giovannoni et al. Oct 2005 B2
7067194 Mao et al. Jun 2006 B2
7108775 Bahatt et al. Sep 2006 B2
7115384 Clark et al. Oct 2006 B2
7123345 Sugihara et al. Oct 2006 B2
7214299 Armstrong May 2007 B2
7250775 Collins et al. Jul 2007 B1
7258837 Yager et al. Aug 2007 B2
7306924 Gomez et al. Dec 2007 B2
7341841 Metzger et al. Mar 2008 B2
7348183 Fritsch et al. Mar 2008 B2
7397540 Lundgren et al. Jul 2008 B2
7413891 Bashir et al. Aug 2008 B2
7429355 Bishop et al. Sep 2008 B2
7435579 Bashir et al. Oct 2008 B2
7451646 Cleland et al. Nov 2008 B2
7481977 Percival et al. Jan 2009 B2
7510637 Barlow et al. Mar 2009 B2
7561789 Border et al. Jul 2009 B2
7564245 Lee Jul 2009 B2
7576307 Yazdanfar et al. Aug 2009 B2
7601300 Blanton et al. Oct 2009 B2
7622078 Pagés Pinyol Nov 2009 B2
7629029 Mao et al. Dec 2009 B2
7642068 Steiner et al. Jan 2010 B2
7651837 Ohno et al. Jan 2010 B2
7670793 Glencross Mar 2010 B2
7678256 Davalos et al. Mar 2010 B2
7687239 Goldberg et al. Mar 2010 B2
7689022 Weiner et al. Mar 2010 B2
7723095 Cleuziat et al. May 2010 B2
7754148 Yu et al. Jul 2010 B2
7829275 Franzen et al. Nov 2010 B2
7842504 Devlin, Sr. Nov 2010 B2
7873268 Segawa et al. Jan 2011 B2
7901624 Hansen et al. Mar 2011 B2
7910062 Yu et al. Mar 2011 B2
7955555 Blecka et al. Jun 2011 B2
8014583 Zahniser Sep 2011 B2
8029746 Yu et al. Oct 2011 B2
8058078 Hansen et al. Nov 2011 B2
8071319 Metzger et al. Dec 2011 B2
8102276 Sugiura Jan 2012 B2
8168443 Yu et al. May 2012 B2
8178602 Mao et al. May 2012 B2
8188438 Li May 2012 B2
8304245 Kuypers et al. Nov 2012 B2
8323466 Kim et al. Dec 2012 B2
8329437 Ayliffe Dec 2012 B1
8335393 Kotani Dec 2012 B2
8354307 Lee Jan 2013 B2
8361298 Sabin et al. Jan 2013 B2
8361299 Sabin et al. Jan 2013 B2
8364409 Rieder et al. Jan 2013 B2
8368964 Xu et al. Feb 2013 B2
8372353 Lee et al. Feb 2013 B2
8372600 Sachs et al. Feb 2013 B2
8391582 Weiner et al. Mar 2013 B2
8421484 Prodan et al. Apr 2013 B2
8460887 Goldberg et al. Jun 2013 B2
8478445 Hansen et al. Jul 2013 B2
8481281 Demirev et al. Jul 2013 B2
8508652 Albu et al. Aug 2013 B2
8512636 Blanton et al. Aug 2013 B2
8513001 Weiss et al. Aug 2013 B2
8563298 Lowery, Jr. et al. Oct 2013 B2
8603769 Feng et al. Dec 2013 B2
8614056 Davis et al. Dec 2013 B2
8635028 Sengupta et al. Jan 2014 B2
8647835 Walsh et al. Feb 2014 B2
8652800 Walsh et al. Feb 2014 B2
8703061 Guzman Apr 2014 B2
8709344 Bishop et al. Apr 2014 B2
8765062 Linder et al. Jul 2014 B2
8779779 Wang et al. Jul 2014 B2
8780181 Olesen et al. Jul 2014 B2
8804105 Ayliffe Aug 2014 B2
8821814 Cho et al. Sep 2014 B2
8828680 Williams et al. Sep 2014 B2
8841118 Robinson et al. Sep 2014 B2
8895255 Goldberg et al. Nov 2014 B1
8911987 Robinson et al. Dec 2014 B2
8932523 Linder et al. Jan 2015 B2
8943588 Speegle et al. Jan 2015 B1
8969072 Robinson et al. Mar 2015 B2
8970826 Liu et al. Mar 2015 B2
9007233 Sugiura Apr 2015 B2
9048771 Ohba et al. Jun 2015 B2
9057714 Gomm et al. Jun 2015 B2
9090462 Straus Jul 2015 B2
9133498 Kwon et al. Sep 2015 B2
9150900 Bishop et al. Oct 2015 B2
9213043 Cook et al. Dec 2015 B2
9248422 Ching et al. Feb 2016 B2
9274132 Wilson et al. Mar 2016 B2
9290382 Straus Mar 2016 B2
9353396 Demirev et al. May 2016 B2
9405288 Ogata Aug 2016 B2
9434937 Metzger Sep 2016 B2
9567621 Robinson et al. Feb 2017 B2
9657327 Metzger et al. May 2017 B2
9677109 Shamsheyeva et al. Jun 2017 B2
9714420 Metzger et al. Jul 2017 B2
9841422 Goldberg et al. Dec 2017 B2
20010009774 Shin et al. Jul 2001 A1
20010053535 Bashir et al. Dec 2001 A1
20020028489 Ammann et al. Mar 2002 A1
20020028519 Yguerabide et al. Mar 2002 A1
20020031795 James et al. Mar 2002 A1
20020119455 Chan Aug 2002 A1
20020127144 Mehta Sep 2002 A1
20020148729 Armstrong Oct 2002 A1
20020155490 Skinner et al. Oct 2002 A1
20020155591 Farina et al. Oct 2002 A1
20020164677 Giovannoni et al. Nov 2002 A1
20020197709 Van der Weide et al. Dec 2002 A1
20030023149 Montemagno et al. Jan 2003 A1
20030032171 Gemmell et al. Feb 2003 A1
20030032173 Farina et al. Feb 2003 A1
20030036054 Ladisch et al. Feb 2003 A1
20030119028 Graves et al. Jun 2003 A1
20030124623 Yager et al. Jul 2003 A1
20030134269 Hirai et al. Jul 2003 A1
20030147132 Behnsen et al. Aug 2003 A1
20030153023 Starzl et al. Aug 2003 A1
20030157587 Gomez et al. Aug 2003 A1
20030170613 Straus Sep 2003 A1
20030186341 Kuhn et al. Oct 2003 A1
20030211566 Gazenko Nov 2003 A1
20030224436 Nelson et al. Dec 2003 A1
20040052426 Landesman Mar 2004 A1
20040089546 Bahatt et al. May 2004 A1
20040168916 Fuchs et al. Sep 2004 A1
20040189311 Glezer et al. Sep 2004 A1
20050048599 Goldberg et al. Mar 2005 A1
20050059105 Alocija et al. Mar 2005 A1
20050112544 Xu et al. May 2005 A1
20050114041 Gawad et al. May 2005 A1
20050118705 Rabbitt et al. Jun 2005 A1
20050121596 Kam et al. Jun 2005 A1
20050202523 Shaw et al. Sep 2005 A1
20050208592 Caron et al. Sep 2005 A1
20050213374 Xu et al. Sep 2005 A1
20050221403 Gazenko Oct 2005 A1
20050238652 Tsuji et al. Oct 2005 A1
20050255445 Van Danime et al. Nov 2005 A1
20050287572 Mathies et al. Dec 2005 A1
20060120916 Kolari et al. Jun 2006 A1
20060141618 Yasuda et al. Jun 2006 A1
20060166184 Yasuda et al. Jul 2006 A1
20060194307 Yasuda et al. Aug 2006 A1
20060243594 Schnelle et al. Nov 2006 A1
20070037225 Metzger et al. Feb 2007 A1
20070202538 Glezer et al. Aug 2007 A1
20070238146 Tyler et al. Oct 2007 A1
20070298513 Starzl et al. Dec 2007 A1
20080014181 Ariff et al. Jan 2008 A1
20080046286 Halsted Feb 2008 A1
20080072664 Hansen et al. Mar 2008 A1
20080138799 Cheng et al. Jun 2008 A1
20080193965 Zeng et al. Aug 2008 A1
20080221805 Andrews Sep 2008 A1
20080241858 Metzger et al. Oct 2008 A1
20090012723 Treado et al. Jan 2009 A1
20090051372 Sethu et al. Feb 2009 A1
20090104689 Kim et al. Apr 2009 A1
20090203063 Wheeler et al. Aug 2009 A1
20090208072 Seibel et al. Aug 2009 A1
20100048428 Coyer et al. Feb 2010 A1
20100075340 Javanmard Mar 2010 A1
20100099139 Ben-David et al. Apr 2010 A1
20100120016 Li et al. May 2010 A1
20100129858 Walsh et al. May 2010 A1
20100248281 Straus Sep 2010 A1
20100267165 Bruls et al. Oct 2010 A1
20110023690 Wilson Feb 2011 A1
20110042582 Ingber et al. Feb 2011 A1
20110117577 Reboud et al. May 2011 A1
20110136165 Vojnovic et al. Jun 2011 A1
20110183856 Agan et al. Jul 2011 A1
20110237446 Treado et al. Sep 2011 A1
20110242308 Igarashi et al. Oct 2011 A1
20110256617 Cocchi et al. Oct 2011 A1
20120028342 Ismagilov et al. Feb 2012 A1
20120077206 Metzger et al. Mar 2012 A1
20120103817 Omori et al. May 2012 A1
20120105837 Ingber May 2012 A1
20120142032 Morgan Jun 2012 A1
20120149584 Olle Jun 2012 A1
20120169863 Bachelet et al. Jul 2012 A1
20120223217 Zheng et al. Sep 2012 A1
20120244519 Olesen et al. Sep 2012 A1
20120258874 Narain et al. Oct 2012 A1
20130017534 Nickel et al. Jan 2013 A1
20130045878 McCue Feb 2013 A1
20130089886 Feng et al. Apr 2013 A1
20130115607 Nielsen et al. May 2013 A1
20130183694 Janetzko et al. Jul 2013 A1
20130217063 Metzger et al. Aug 2013 A1
20130271060 Messersmith et al. Oct 2013 A1
20130295588 Watkins et al. Nov 2013 A1
20130295597 DeWitte et al. Nov 2013 A1
20130324437 Pogliano et al. Dec 2013 A1
20130345525 Kline Dec 2013 A1
20140038171 Metzger et al. Feb 2014 A1
20140179726 Bajaj et al. Jun 2014 A1
20140199719 Shih et al. Jul 2014 A1
20140234949 Wasson et al. Aug 2014 A1
20140278136 Shamsheyeva et al. Sep 2014 A1
20140278143 Garstecki et al. Sep 2014 A1
20140323340 Goldberg et al. Oct 2014 A1
20140343868 Colwell et al. Nov 2014 A1
20150168290 Shachaf Jun 2015 A1
20150225762 Metzger et al. Aug 2015 A1
20150293270 Jarvius et al. Oct 2015 A1
20150301002 DeWitte et al. Oct 2015 A1
20150337351 Metzger Nov 2015 A1
20160010138 Shamsheyeva et al. Jan 2016 A1
20160051985 Knight et al. Feb 2016 A1
20160238826 Shields et al. Aug 2016 A1
20160279633 Bachelet et al. Sep 2016 A1
20160289729 Richards et al. Oct 2016 A1
20170023599 Richards et al. Jan 2017 A1
20170029864 Straus Feb 2017 A1
20170218426 Shamsheyeva et al. Aug 2017 A1
20170234781 Prisbrey et al. Aug 2017 A1
20180080932 Goldberg et al. Mar 2018 A1
20180135093 Ashby et al. May 2018 A1
Foreign Referenced Citations (68)
Number Date Country
772760 May 2004 AU
498920 Aug 1992 EP
1648286 Apr 2006 EP
2 645 108 Oct 2013 EP
2 987 851 Feb 2016 EP
2507663 Feb 2017 EP
1520733 Aug 1978 GB
52102491 Aug 1977 JP
58198759 Nov 1983 JP
H11505405 May 1999 JP
2001509008 Jul 2001 JP
2002500892 Jan 2002 JP
2002502597 Jan 2002 JP
2002330799 Nov 2002 JP
2003527601 Sep 2003 JP
200481019 Mar 2004 JP
2004513628 May 2004 JP
WO 1989001162 Feb 1989 WO
WO 8910566 Nov 1989 WO
WO 1990011525 Oct 1990 WO
WO 1991004491 Apr 1991 WO
WO 1993013197 Jul 1993 WO
WO 1994002831 Feb 1994 WO
WO 1994011728 May 1994 WO
WO 1995008640 Mar 1995 WO
WO 1995028641 Oct 1995 WO
WO 1996014431 May 1996 WO
WO 1998022618 May 1998 WO
WO 1998022808 May 1998 WO
WO 1998040741 Sep 1998 WO
WO 1999020789 Apr 1999 WO
WO 1999037799 Jul 1999 WO
WO 1999040174 Aug 1999 WO
WO 1999058948 Nov 1999 WO
WO 2000024941 May 2000 WO
WO 2001031332 May 2001 WO
WO 2001069230 Sep 2001 WO
WO 2001079529 Oct 2001 WO
WO 2002038724 May 2002 WO
WO 2002088299 Nov 2002 WO
WO 2003012525 Feb 2003 WO
WO 2003022999 Mar 2003 WO
WO 2003025208 Mar 2003 WO
WO 2003048736 Jun 2003 WO
WO 2003065009 Aug 2003 WO
WO 2003073100 Sep 2003 WO
WO 2005027714 Mar 2005 WO
WO 2006015374 Feb 2006 WO
WO 2006028601 Mar 2006 WO
WO 2006066216 Jun 2006 WO
WO 2006113930 Oct 2006 WO
WO 2006135904 Dec 2006 WO
WO 2009124068 Oct 2009 WO
WO 2010062350 Jun 2010 WO
WO 2010062352 Jun 2010 WO
WO 2011035304 Mar 2011 WO
WO 2012122314 Sep 2012 WO
WO 2012162133 Nov 2012 WO
WO 2013072069 May 2013 WO
WO 2013130875 Sep 2013 WO
WO 2013177277 Nov 2013 WO
WO 2014040088 Mar 2014 WO
WO 2014100456 Jun 2014 WO
WO 2014145899 Sep 2014 WO
WO 2014153194 Sep 2014 WO
WO 2014169921 Oct 2014 WO
WO 2016037051 Mar 2016 WO
WO2016207065 Dec 2016 WO
Non-Patent Literature Citations (218)
Entry
Unknown, “Bacterial Counts—Quantitative Analysis of Microbes,” Biology 251 General Microbiology Lab, Jul. 30, 2013, pp. 1-5, retrieved from internet: URL:http://biolabs.tmcc.edu/Micro%20Web/BacterialCounts.pdf [retrieved on Oct. 21, 2016].
EP 14762411.8 Extended European Search Report dated Nov. 7, 2016 (11 pages).
PCT/US2016/025075, International Search Report and Written Opinion dated Nov. 15, 2016 (36 pages).
Levin-Reisman et al., “Automated Imagining With ScanLag Reveals Previously Undetectable Bacterial Growth Phenotypes,” Nature Methods 7:737-739, 2010.
Tokuda et al., “Optical and Electric Multifunctional CMOS Image Sensors for On-Chip Biosensing Applications,” Materials 4:84-102, 2011.
EP16200084.8 Partial European Search Report dated Mar. 1, 2017.
Choi et al., “Rapid antibiotic susceptibility testing by tracking single cell growth in a microfluidic agarose channel system,” Lab Chip 13:280-287, 2013.
PCT/US2016/025075 Invitation to Pay Additional Fees with Partial International Search dated Jul. 6, 2016 (8 pages).
EP 13835702.5, European Supplementary Search Report dated Jun. 24, 2016 (12 pages).
EP 13835702.5, Rules 70(2) and 70a(2) EPC Communication dated Jul. 12, 2016, 2016 (1 page).
EP 14762411.8 Partial Supplementary European Search Report dated Jul. 29, 2016 (10 pages).
EP 16200084.8 Extended European Search Report dated Aug. 1, 2017 (17 pages).
Palarasah et al., “Sodium Polyanethole Sulfonate as an Inhibitor of Activation of Complement Function in Blood Culture Systems,” J Clin Microbiol. 48:908-914, 2010.
EP 13835702.5 Office Action dated Oct. 16, 2017 (9 pages).
Isse et al., “Digital Transplantation Pathology: Combining Whole Slide Imaging, Multiplex Staining and Automated Image Analysis,” Am J Transplant. 12:27-37, 2012.
U.S. Appl. No. 15/586,132, filed May 3, 2017.
U.S. Appl. No. 15/827,187, filed Nov. 30, 2017.
U.S. Appl. No. 15/849,297, filed Dec. 20, 2017.
EP 16192372.7 Extended European Search Report and Written Opinion dated Feb. 28, 2018 (11 pages).
Accelerate Diagnostics: “Fast Phenotypic Antibiotic Susceptibility Testing: Connie Price, M.D.,” YouTube, Aug. 28, 2015, pp. 1-6, XP054976622, Retrieved from the Internet: URL:https://www.youtube.com/watch?v=1n1GW54atXE&index=3&list=PLsmqpsknnk2_ENp8Xd3BhK0vu9nfU0p6y [retrieved on Jun. 22, 2016].
Accelerate Diagnostics: “Accelerate ID/AST,” Vimeo, May 18, 2015, pp. 1-6, XP054976621, Retrieved from the Internet: URL:https://vimeo.com/128112270 [retrieved on Jun. 22, 2016].
Alere, Inc., “Adult Isolator Tube Solution Material Safety Data Sheet,” (2010).
Aminian et al., “A Conformal Bayesian Network for Classification of Mycobacterium tuberculosis Complex Lineages,” BMC Bioinformatics, 11(Suppl 3): S4 (2010).
Anzaldi et al., “Overcoming the Heme Paradox: Heme Toxicity and Tolerance in Bacterial Pathogens,” Immun. 78(12): 4977-4989 (2010).
Ateya et al., “Volume Cytometry: Microfluidic Sensor for High-Throughput Screening in Real Time,” Analytical Chem., 77:1290-1294, (2005).
Atlas and Snyder, Handbook of Media for Clinical Microbiology, 2006. CRC press.
Bae et al., “Immunosensor for Detection of Yersinia Enterocolitica Based on Imaging Ellipsometry,” Analytical Chem., 76:1799-1803, (2004).
Baker et al., “The Bactericidal Action of Synthetic Detergents,” J Exp Med. 74:611-620, 1941.
Balaban et al., “Bacterial Persistence as a Phenotypic Switch,” Science, 305:1622-1625, (2004).
Barton et al., “Measurement of Bacterial Growth Rates on Polymers,” J. Biomed. Mater Res., 32:271-278, (1996).
Bayoudh et al., “Electrical Detection and Characterization of Bacterial Adhesion Using Electrochemical Impedance Spectroscopy-Based Flow Chamber,” Colloids and Surfaces A: Physicochem. Eng. Aspects, 318, pp. 291-300, (2008).
Beaglehole, “Performance of a Microscopic Imaging Ellipsometer,” Rev. Sci. Instrum., 59:12, pp. 2557-2559, (1988).
Belding et al., “Effect of Sodium Polyanetholesulfonate on Antimicrobial Systems in Blood,” Appl. Microbiol. 24(5): 691-698 (1972).
Benecky et al., “Simultaneous Detection of Multiple Analytes Using Copalis Technology: A Reduction to Practice,” Clin. Chem., 44:9, pp. 2052-2054, (1998).
Boehm et al., “On-Chip Microfluidic Biosensor for Bacterial Detection and Identification,” Sensors and Actuators, 126, pp. 508-514, (2007).
Bridson, E.Y., and Gould, G.W., “Quantal Microbiology,” Lett. Appl. Microbiology, 30:95-98, (2000).
Burnham C-1358: Poster—“Rapid Detection of Klebsiella pneumoniae Carbapenemase (KPC) Producing Isolates Using the BACcel™ Digital Microscopy System,” Presented at ASM May 18, 2013, 2013, Denver, CO.
Burnham et al., “Rapid Ertapenem Susceptibility Testing and Klebsiella pneumoniae Carbapenemase (KPC) Phenotype Detection in Klebsiella pneumoniae Using Automated Microscopy of Immobilized Live Bacterial Cells,” J Clin Microbiol., Jan. 3, 2014.
Cabrera et al., “Continuous Concentration of Bacteria in a Microfluidic Flow Cell Using Electrokinetic Techniques,” Electrophoresis 22:355-362, 2001.
Chan et al., “Evaluation of Lysis Filtration as an Adjunct to Conventional Blood Culture,” J. Clin. Pathol. 39:89-92 (1986).
Cheung et al., “Microfluidic Impedance-Based Flow Cytometry,” Cytometry A, 77A, pp. 648-666, (2010).
Cooper et al. D-4013: Poster—“Potential Impact of Rapid Phenotype Identification on Antimicrobial Prescribing,” Presented at the 48th ICAAC and IDSA Oct. 28, 2008, Washington, DC.
Dai et al., “Electrokinetic Trapping and Concentration Enrichment of DNA in a Microfluidic Channel,” J. Am. Chem. Soc., 125:13026-13027, (2003).
Daims et al., “Quantification of Uncultured Microorganisms by Fluorescence Microscopy and Digital Image Analysis,” Appl. Microbiol. Biotechnol., 75:237-248, (2007).
De Brabander et al., “Detection of Gold Probes With Video-Enhanced Contrast Microscopy: Nanovid Microscopy,” Amer. J., 185, pp. 282-295, (1989).
Delehanty and Ligler, “A Microarray Immunoassay for Simultaneous Detection of Proteins and Bacteria,” Anal. Chem., 74, pp. 5681-5687, (2002).
Desai and Armstrong, “Separation, Identification, and Characterization of Microorganisms by Capillary Electrophoresis,” Microbiology and Molecular Biology Reviews, 67:38-51, (2003).
Dorn et al., “Blood Culture Technique Based on Centrifugation: Developmental Phase,” J. Clin. Micro. 3(3): 251-257 (1976).
Douglas et al. Poster—“Rapid Microbiological Identification and Major Drug Resistance Phenotyping with Novel Multiplexed Automated Digital Microscopy (MADM) for Ventilator-Associated Pneumonia (VAP) Surveillance,” Presented at ATS 2011 May 16, 2011, Denver, CO.
Douglas et al., Rapid Automated Microscopy for Microbiological Surveillance of Ventilator-associated Pneumonia, Am T Respir Crit Care Med. 191:566-573, 2015.
Dwek et al., “Synchronization of Cell Division in Microorganisms by Percoll Gradients,” J. Bacteriol. 144(1):17-21 (1980).
Elfwing et al., “Observing Growth and Division of Large Numbers of Individual Bacteria by Image Analysis,” Appl. Environ. Micro., 70:675-678, (2004).
Elghanian et al., “Selective Colorimetric Detection of Polynucleotides Based on the Distance-Dependent Optical Properties of Gold Nanoparticles,” Science, 277:1078-1081, (1997).
Ertl et al., “Electrochemical Biosensor Array for the Identification of Microorganisms Based on Lectin-Lipopolysaccharide Recognition,” Analytical Chem., 73:4241-4248, (2001).
Ertl et al., “Rapid Identification of Viable Escherichia coli Subspecies with Electrochemical Screen-Printed Biosensor Array,” Biosensors Bioelectronics, 18:907-916, (2003).
Eun et al., “Encapsulating Bacteria in Agarose Microparticles Using Microfluidics for High-Throughput Cell Analysis and Isolation,” ACS Chem. Biol., 18:260-266, (2011).
Fesenko et al, “Biosensing and Monitoring of Cell Populations Using the Hydrogel Bacterial Microchip,” Biosens Bioelectron. 20:1860-1865, 2005.
Forero et al., “Automatic Identification Techniques of Tuberculosis Bacteria,” Proc. SPIE 5203, Applications of Digital Image Processing XXVI, (Tescher, A.G., Ed.) SPIE Proceedings, 5203:71-81, (2003).
Friedman et al., “Precise Temporal Modulation in the Response of the SOS DNA Repair Network in Individual Bacteria,” PLoS Bio. 3:1261-1263, (2005).
Gadkari, “Optimal Hydrogels for Fast and Safe Delivery of Bioactive Compounds,” A Thesis Submitted to the Faculty of Drexel University, (2007).
Gamage et al. 2556: Poster—“Rapid Detection of Clinically Important Staphylococcus aureus Resistance Phenotypes Directly from Positive Blood Cultures Using Automated Microscopy,” Presented at ASM2014 May 20, 2014, Boston, MA.
Gao et al., “Epipolarization Microscopic lmmunogold Assay: A Combination of lmmunogold Silver Staining, ELISA and Epipolarization Microscopy,” Biotech. & Histochem., 70:211-216, (1995).
Gast, R.K. et al., “Detection of Salmonella entertidis in Incubated Pools of Egg Contents by Fluorescence Polarization and Lateral Flow Immunodiffusion,” Poultry Science, 82:687-690, (2003).
Gawad et al., “Micromachined Impedance Spectroscopy Flow Cytometer for Cell Analysis and Particle Sizing,” Lab on a Chip, 1:76-82, (2001).
Geerts et al., “Nanovid Microscopy,” Nature, 1991, 351:765-766, (1991).
Geesey and White, “Determination of Bacterial Growth and Activity at Solid-Liquid Interfaces,” Annu. Rev. Microbiol., 44, pp. 579-602, (1990).
Gomez et al., “Microfluidic Biochip for Impedance Spectroscopy of Biological Species,” Biomedical Microdevices, 3:3, pp. 201-209, (2001).
Greef et al., “Identification and Growth Rate Quantitation of Individual Bacterial Clones Using a Novel Microfluidic Concentration Device,” Accelr8 Technology Corporation (1 page), 2006.
Hach Company, “Heterotrophic Bacteria, Pour Plate Method,” Edition 7 (10 pages), 2012.
Hance et al. K-392: Poster—“Rapid Identification of Live Acinetobacter spp. in Bronchoalveolar Lavage Specimens by Automated Immunofluorescence Microscopy,” Presented at the 47th ICAAC Sep. 27, 2007.
Hance et al. C-065: Poster—“A Rapid Indirect Enzyme-Linked Immunosorbent Assay for Identification of Acinetobacter spp. from Cultured Isolates,” Presented at the American Society for Microbiology 108th General Meeting Jun. 2, 2008.
Hance et al. P0539: Poster—“Pathogen Identification from Positive Blood Cultures Using Automated Sample Preparation and Automated Fluorescent in situ Hybridization (FISH),” Presented at ECCMID 2014, May 11, 2014, Barcelona, Spain.
Hance et al. Poster 2032: Poster—“Rapid Bacterial Identification Directly from Positive Blood Cultures Using Automated Sample Preparation and Multiplexed Fluorescence in situ Hybridization (FISH),” ASM2014, Boston, MA May 20, 2014.
Heileman et al., “Dielectric Spectroscopy as a Viable Biosensing Tool for Cell and Tissue Characterization and Analysis,” Biosensors and Bioelectronics, 49:348-359, (2013).
Huang et al., “Electric Manipulation of Bioparticies and Macromolecules on Microfabricated Electrodes,” Analytical Chem., 73, pp. 1549-1559, (2001).
Huang et al., “Lysozyme for Capture of Microorganisms on Protein Biochips,” Enzyme and Microbial. Technol., 33:958-966, (2003).
Inverness Medical Group, “Wampole Isostat Microbial Tubes, Instructions for Use and Supplementary Application Notes,” (2008).
Iregui et al., “Clinical Importance of Delays in the Initiation of Appropriate Antibiotic Treatment for Ventilator-Associated Pneumonia,” Chest 122:262-268, 2002.
Kumar et al., “Duration of Hypotension Before Initiation of Effective Antimicrobial Therapy is the Critical Determinant of Survival in Human Septic Shock,” Crit Care Med. 34:1589-1596, 2006.
Jampachaisri et al., “Classification of oligonucleotide fingerprints: application for microbial community and gene expression analyses,” Bioinformatics 21:3122-3130 (2005).
Ji et al., “Real-time Detection of Bacterial Contamination in Dynamic Aqueous Environments Using Optical Sensors,” Analytical Chem., 76:1411-1418, (2004).
Jin et al., “A Biosensor Concept Based on Imaging Ellipsometry for Visualization of Biomolecular Interactions,” Analytical Biochem., 232, pp. 69-72, (1995).
Kastenholz, B. “Comparison of the Electrochemical Behavior of the High Molecular Mass Cadmium Proteins in Arabidopsis thaliana and in Vegetable Plants on Using Preparative Native Continuous Polyacrylamide Gel Electrophoresis (PNC-PAGE),” Electroanalysis 18:103-106 (2006).
Kim and Soh, “Simultaneous Sorting of Multiple Bacterial Targets Using Integrated Dielectrophoretic-Magnetic Activated Cell Sorter,” Lab Chip 9:2313-2318, 2009.
Kim et al., “Programmed Trapping of Individual Bacteria Using Micrometre-Size Sieves,” Lab on a Chip, 11, pp. 1089-1095, (2011).
Koh et al., “Integrating Polymerase Chain Reaction, Valving, and Electrophoresis in a Plastic Device for Bacterial Detection,” Analytical Chem., 75:4591-4598, (2003).
Kremser, et al., “Capillary Electrophoresis of Biological Particles: Viruses, Bacteria, and Eukaryotic Cells,” Electrophoresis 25: 2282-2291 (2004).
Kubitschko et al., “Sensitivity Enhancement of Optical Immunosensors with Nanoparticles,” Analytical Biochem., 253:112-122, (1997).
Kuehn et al., “Automated Confocal Laser Scanning Microscopy and Semiautomated Image Processing for Analysis of Biofilms,” Appl. Environ. Microbio., 64:4115-4127, (1998).
Lagally et al., “Integrated Portable Genetic Analysis Microsystem for Pathogen/Infectious Disease Detection,” Analytical Chem., 76:3162-3170, (2004).
Lawrence et al., “Computer-Enhanced Darkfield Microscopy for the Quantitative Analysis of Bacterial Growth and Behavior on Surfaces,” J. Microbial. Methods 10:123-138, (1989).
Lerner, “Bayesian Fluorescence In Situ Hybridisation Signal Classification,” Artif. Intell. Med. 30:301-316 (2004).
Lisby et al. ePoster “Performance of the new Accelerate ID/AST System in Highly Resistant Acinetobacter baumannii Bloodstream Infection Isolates, Compared to Routine Laboratory Testing,” ECCMID Apr. 23, 2015, Copenhagen, Denmark.
Liu et al., “CMEIAS: A Computer-Aided System for the Image Analysis of Bacterial Morphotypes in Microbial Communities,” Micro. Ecology., 41:173-194, (2001).
Lloyd and Hayes, “Vigour, Vitality and Viability of Microorganisms,” FEMS Microbio. Lett. 133:1-7, (1995).
Lochhead, “Microfluidic Devices that Capture Bacteria for Growth and Kill Analysis,” Nov. 14, 2006, XP055207195, retrieved from the Internet: URL:http://acceleratediagnostics.com/docs/AVS_2006_Capture.pdf [retrieved on Aug. 11, 2015].
Luna et al., “Appropriateness and Delay to Initiate Therapy in Ventilator-Associated Pneumonia,” Eur Respir J. 27:158-164, 2006.
Maeyama et al., “Confocal Imaging of Biofilm Formation Process Using Fluoroprobed Escherichia coli and Fluorostained Exopolysaccharide,” J. Biomed. Mater Res., 70:274-282, (2004).
Magnusdottir et al. “Collection of Capillary Electrophoresis Fractions on a Moving Membrane,” From Methods in Molecular Biology, vol. 162: Capillary Electrophoresis of Nucleic Acids, vol. 1: Introduction to the Capillary Electrophoresis of Nucleic Acids. 22: 323-331 (2001).
Markx et al., “Dielectrophoretic Separation of Cells: Continuous Separation,” Biotechnol. Bioeng., 45:337-343, (1995).
Markx, G.H. et al., “Dielectrophoretic Characterization and Separation of Micro-Organisms” Microbiology, 140, pp. 585-591 (1994).
Meinders et al., “In Situ Enumeration of Bacterial Adhesion in a Parallel Plate Flow Chamber—Elimination or in Focus Flowing Bacteria From the Analysis,” J. Microbiol. Methods, 16:119-124, (1992).
Metzger et al. C-163: Poster—“Direct Observation of Inducible Clindamycin Resistance in Staphylococcus aureus Using Single Live Cell Imaging,” Presented at the American Society for Microbiology General Meeting May 23, 2006.
Metzger C-032: Poster—“Direct Identification of Methicillin Resistant Staphylococcus aureus (MRSA) Using Small Numbers of Immobilized Cells and Response to Oxacillin (OCA) by Automated Growth Analysis,” Presented at the American Society for Microbiology 107th General Meeting, May 22, 2007.
Metzger et al. D-892: Poster—“Identification of mecA in Staphylococcus aureus Using Small Numbers of Immobilized Cells and the Response to Cefoxitin (FOX) by Automated Growth Analysis,” Presented at the 47th ICAAC Sep. 28, 2007.
Metzger et al. C-005: Poster—“Direct identification of MRSA and MLSB Phenotypes in Staphylococcus aureus Using Small Numbers of Immobilized Cells,” Presented at the American Society for Microbiology 108th General Meeting Jun. 2, 2008.
Metzger et al. C-145: Poster—“Direct Detection and Enumeration of Viable Bacteria in Human Bronchoalveolar Lavage Specimens Using Automated Growth Rate Analysis,” Presented at the American Society for Microbiology 108th General Meeting Jun. 2, 2008.
Metzger et al. D-282: Poster—“Direct Identification of the ESBL Phenotype in Enterobacteriaceae Isolates Using Small Numbers of Immobilized Cells,” Presented at the 48th ICAAC and IDSA Oct. 25, 2008, Washington, DC.
Metzger et al. C-207: Poster—“Rapid Identification of Resistance Phenotypes in Gram-Negative Bacilli Using Automated Digital Microscopy,” Presented at the 109th General Meeting of the ASM, Philadelphia, PA, May 23, 2009.
Metzger et al. C-1140: Poster—“Rapid Quantitation and Identification of Pseudomonas aeruginosa, Staphylococcus aureus, and Acinetobacter baurnannii in Bronchoalveolar Lavage Fluid,” Presented at the 110th General Meeting of the ASM May 24, 2010, San Diego, CA.
Metzger et al. Poster: “Same-Day ID and Resistance Phenotyping Directly from Respiratory Specimens by Automated Microscopy,” Presented at ASM 2011, New Orleans, May 22, 2011.
Metzger et al. Poster—“Automated 4-Hour Detection of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus (hVISA),” Presented at ASM 2011 May 22, 2011, New Orleans.
Metzger et al. D-791: Poster—“Direct-From-Remnant-Specimen Quantitative Identification Using Automated Microscopy,” Presented at the 50th ICAAC, Sep. 13, 2010, Boston, MA.
Metzger and Dunne D-102: Poster—“Same-Shift ID Directly from Respiratory Specimens by Automated Microscopy,” Presented at 51st ICAAC Sep. 17, 2011, Chicago, IL.
Metzger et al. C-157: Poster—“3-Hour ESBL Detection from Positive Blood Cultures Using Multiplexed Automated Digital Microscopy (MADM),” Presented at ASM 2012 Jun. 17, 2012, San Francisco, CA.
Metzger et al. C-751: Poster—“Rapid and Automated Specimen Preparation for Clinical Microbiology,” Presented at ASM 2012 Jun. 17, 2012, San Francisco, CA.
Metzger D-1410: Poster—“Same-Day Blood Culture with Digital Microscopy,” Presented at ICAAC 2012 Sep. 11, 2012, San Francisco, CA.
Metzger et al., “Rapid Simultaneous Identification and Quantitation of Staphylococcus aureus and Pseudomonas aeruginosa Directly from Bronchoalveolar Lavage Specimens Using Automated Microscopy,” Diagn Microbiol Infect Dis. 79:160-165, 2014. Diagn Microbiol Infect Dis. Epublished Dec. 7, 2013.
Miller et al., “SOS Response Induction by Beta-Lactams and Bacterial Defense Against Antibiotic Lethality,” Science, 305, pp. 1629-1631, (2004).
Mishra et al., “On-Chip Micro-Biosensor for the Detection of Human CD4+ Cells Based on AC Impedance and Optical Analysis,” Biosensors and Bioelectronics, 21:696-704, (2005).
Moffitt et al., “The Single-Cell Chemostat: An Agarose-Based, Microfluidic Device for High-Throughput, Single-Cell Studies of Bacteria and Bacterial Communities,” Lab Chip 12:1487-1494, 2012.
Mohamad et al., “Bacteria Identification from Microscopic Morphology Using Naïve Bayes,” IJCSEIT 4:1-9, 2014.
Molin et al., “Rapid Detection of Bacterial Growth in Blood Cultures by Bioluminescent Assay of Bacterial ATP,” J. Clin. Microbiol., 18:521-525 (1983).
Mueller et al., “Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves Versus MIC,” Antimicrob. Agents Chemother., 48:369-377, (2004).
Oheim, “High-Throughput Microscopy Must Re-Invent the Microscope Rather Than Speed up its Functions,” British Journal of Pharmacology, 152:1-4, (2007).
Okano et al., “Using Microparticle Labeling and Counting for Attomole-Level Detection in Heterogeneous Immunoassay,” Analytical Biochem., 202:120-125, (1992).
Orjih, “Heme Polymerase Activity and the Stage Specificity of Antimalarial Action of Chloroquine,” J. Pharm. Exp. Ther. 282(1):108-112 (1997).
Ozkan et al., “Electro-Optical Platform for the Manipulation of Live Cells,” Langmuir, 19:1532-1538, (2003).
Plowman, “Planar Integrated Optical Methods for Examining Thin Films and Their Surface Adlayers,” Biomaterials, 19:341-355, (1998).
Price et al., “Rapid Antibiotic Susceptibility Phenotypic Characterization of Staphylococcus aureus Using Automated Microscopy of Small Numbers of Cells,” J Microbiol Methods. 98:50-58, 2014.
Price et al. ePoster—“Rapid Identification and Antimicrobial Susceptibility Testing of Bacteria in Bloodstream Infections Using the Accelerate ID/AST Technology,” ECCMID Apr. 23, 2015, Copenhagen, Denmark.
Probst et al., “Polydimethylsiloxane Sub-Micron Traps for Single-Cell Analysis of Bacteria,” Micromachines, 4:357-369, (2013).
Rabinovitch et al., “Removal and Inactivation of Staphylococcus epidermidis Biofilms by Electrolysis,” Applied and Environmental Microbiology, 72:6364-6366, (2006).
Rajagopal et al., “Eight Gram-Negative Bacteria are 10,000 Times More Sensitive to Cationic Detergents than to Anionic Detergents,” Can J Microbiol. 49:775-779, 2003.
RMM Product Matrix, http://rapidmicromethods.com/files/matrix.php, accessed Jul. 27, 2016. (13 pages).
Rohner et al., “Advantage of Combining Resin with Lytic BACTEC Blood Culture Media,” J. Clin. Micro. 35(10):2634-2638 (1997).
Rohner et al., “Evaluation of the New Improved BHI-Lysis Blood Culture Medium for the BCB Roche System,” Eur. J. Clin. Micro. Infect. Dis. 10:620-624, 1991.
Rosch et al., “Chemotaxonomic Identification of Single Bacteria by Micro-Raman Spectroscopy: Application to Clean-Room-Relevant Biological Contaminations,” Applied and Environmental Microbiology, 71:1626-1637, (2005).
Rose et al., “Using the Membrane Filter in Clinical Microbiology,” Med. Lab. 3: 22-23, 29, 43, 1969. Note: The numbered pages omitted from this article are advertisements.
Rowe et al., “Array Biosensor for Simultaneous Identification of Bacterial, Viral, and Protein Analytes,” Analytical Chem., 71:3846-3652, (1999).
Salmon et al., “Video-Enhanced Differential Interference Contrast Light Microscopy,” BioTechniques, 7:624-633, (1989).
Sapsford et al., “Detection of Campylobacter and Shigella Species in Food Samples Using an Array Biosensor,” Analytical Chem., 76:433-440, (2004).
Schrot et al., “Method for Radiorespirometric Detection of Bacteria in Pure Cultures and in Blood,” Appl. Micro. 26(2): 867-873 (1973).
Shamsheyeva et al. 2538: Poster—“Rapid Antimicrobial Susceptibility Testing of Non-Fermenting Gram-Negative Bacilli Directly from Positive Blood Cultures by Automated Microscopy,” Presented at ASM2014, May 20, 2014, Boston, MA.
Shamsheyeva et al. 2555: Poster—“Evaluation of an Antimicrobial Susceptibility Testing Algorithm to Determine Minimum Inhibitory Concentration Using Growth of Immobilized Staphylococcal Cells Measured by Automated Microscopy,” Presented at ASM2014, May 20, 2014, Boston, MA.
Shamsheyeva et al. D-873: Poster “Evaluation of an Antimicrobial Susceptibility Testing Algorithm for Gram-Positive Bacteria Directly from Positive Blood Culture Using Automated Microscopy Analysis of Susceptibility Patterns,” Presented at ICAAC Sep. 7, 2014, Washington, DC.
Shamsheyeva et al. P0332: Poster—“Next Generation Automated Phenotypic Antibiotic Susceptibility Testing Utilizing Automated Microscopy Analysis of Bacterial Cells,” Presented at ECCMID 2014 May 10, 2014, Barcelona, Spain.
Shamsheyeva et al. P0335: Poster—“5-Hour Antibiotic Susceptibility Testing of Enterococcus faecium and E. faecalis, and Acinetobacter baumannii Directly from Positive Blood Cultures Using Automated Microscopy,” Presented at ECCMID 2014 May 10, 2014, Barcelona, Spain.
Sippy, et al., “Rapid Electrochemical Detection and Identification of Catalase Positive Micro-Organisms”, Biosensors & Bioelectronics, 18:741-749, (2003).
Stewart et al., “Aging and Death in an Organism that Reproduces by Morphologically Symmetric Division,” PLoS Biology, 3:295-300 (2005).
Stimpson et al., “Real-Time Detection of DNA Hybridization and Melting on Oligonucleotide Arrays by Using Optical Wave Guides,” Genetics, Proc. Natl. Acad. Sci. USA, 92:6379-6383, (1995).
Stuart, “The Value of Liquid for Blood Culture,” J. Clin. Path. 1:311-314 (1948).
Sun et al., “Single-Cell Microfluidic Impedance Cytometry: A Review,” Microfluidics and Nanofluidics, 8:423-443, (2010).
Suo et al., “Immunoimmobilization of Living Salmonella for Fundamental Studies and Biosensor Applications,” Salmonella—A Diversified Superbug, 25:497-522, (2012).
Taton et al., “Two-Color Labeling of Oligonucleotide Arrays via Size-Selective Scattering of Nanoparticle Probes,” J. Am. Chem. Soc., 123, pp. 5164-5165, (2001).
Tison, D.L., “Culture Confirmation of Escherichia coli Serotype 0157:H7 by Direct Immunofluorescence,” J. Clin. Microbio., 28:612-613, (1990).
Tsang et al., “Characterization of Murine Monoclonal Antibodies Against Serogroup B Salmonellae and Application as Serotyping Reagents,” J. Clin. Micro., 29:1899-1903, (1991).
Van der Borden et al., “Electric Current-Induced Detachment of Staphylococcus epidermidis Biofilms from Surgical Stainless Steel, Applied and Environmental Microbiology,” Applied and Environmental Microbiology, 70:6871-6874, (2004).
Van Soestbergen and Lee, “Pour Plates or Steak Plates?,” Appl Microbiol. 18:1092-1093, 1969.
Varshney et al., “A Label-Free, Microfluidics and Interdigitated Array Microelectrode-Based Impedance Biosensor in Combination with Nanoparticles Immunoseparation for Detection of Escherichia coli O157:H7 in Food Samples,” Sensors and Actuators, 128:99-107, (2007).
Vega, et al., “Effect of Ionic Strength and Porosity on Ion Diffusion in Agarose Gels,” Summer Bioengineering Conference, Sonesta Beach Resort in Key Biscayne, Florida, 1-2 (2003).
Vener et al., “A Novel Approach to Nonradioactive Hybridization Assay of Nucleic Acids Using Stained Latex Particles,” Analytical Biochem., 198:308-311, (1991).
Von Haebler et al., “The Action of Sodium Polyanethol Sulphonate (“Liquoid”) on Blood Cultures,” J. Pathol. Bacteriol. 46(2): 245-252 (1938).
Wallace et al. D-918: Poster—“Rapid Identification of Gram-negative Bacteria in Positive Blood Culture Broth Using a Multiplex Fluorescence in situ Hybridization (FISH) Assay and Automated Microscopy,” Presented at ICAAC Sep. 7, 2014, Washington, DC.
Weeratna et al., “Gene Expression Profiling: From Microarrays to Medicine”, J. Clin. Immunol., 24:213-224, (2004).
Willaert, Chapter 12 in Fermentation Microbiology and Biotechnology: Cell Immobilization and its Applications in Biotechnology: Current Trends and Future Prospects, p. 313-368, 2006.
Wit and Busscher, “Application of an Artificial Neural Network in the Enumeration of Yeasts and Bacteria Adhering to Solid Substrata,” J. Microbio. Methods, 32:281-290 (1998).
Wu et al., “Microfluidic Continuous Particle / Cell Separation via Electroosmotic-Flow-Tuned Hydrodynamic Spreading,” J. Micromech. Microeng., 17:1992-1999, (2007).
Yang et al., “Electrical/ Electrochemical Impedance for Rapid Detection of Foodborne Pathogenic Bacteria,” Biotechnology Advances, 26:135-150, (2008).
Yeung et al., “Bayesi an Model Averaging: Development of an Improved Multi-Class, Gene Selection and Classification Tool for Microarray Data,” Bioinformatics 21:2394-2402 (2005).
Zhou, et al., “Automated Image Analysis for Quantitative Fluorescence In Situ Hybridization with Environmental Samples,” App. Environ. Microbio. 73(a):2956-2962 (2007).
Zierdt et al., “Development of a Lysis-Filtration Blood Culture Technique,” J. Clin. Micro. 5(1):46-50 (1977).
Zierdt et al., “Lysis-Filtration Blood Culture Versus Conventional Blood Culture in a Bacteremic Rabbit Model,” J Clin Microbiol. 15:74-77, 1982.
Zierdt, “Blood-Lysing Solution Nontoxic to Pathogenic Bacteria,” J. Clin. Micro., 15(1):172-174 (1982).
Zierdt, “Simplified Lysed-Blood Culture Technique,” J. Clin. Micro. 23(3):452-455 (1986).
CIPO; Office Action dated Jan. 27, 2014 in Canadian Application No. 2,532,414.
CIPO; Office Action dated Mar. 26, 2015 in Canadian Application No. 2,532,414.
EPO; European Office Action dated Jul. 10, 2014 in Application No. EP 04809482.5.
EPO; European Office Action dated Jun. 17, 2010 in Application No. EP 04809482.5.
EPO; European Office Action dated Mar. 13, 2008 in Application No. EP 04809482.5.
EPO; European Office Action dated Mar. 3, 20.14 in Application No. EP 05854636.7.
EPO; European International Search Report and Written Opinion for PCT/US2015/032290, dated Aug. 24, 2015 (13 pages).
EPO; European Search Report dated Aug. 5, 2004 in Application No. EP 98911454.
EPO; European Search Report dated Feb. 13, 2013 in Application No. EP 05854636.7.
EPO; European Search Report dated Oct. 15, 2007 in Application No. EP 03716230.2.
EPO; Intention to Grant dated May 21, 2015 in Application No. 12754797.4.
EPO; Supplementary European Search Report dated Oct. 19, 2007 in Application No. EP 04809482.5.
EPO; Supplementary European Search Report dated Sep. 24, 2014 in Application No. 12754797.4.
EPO; Partial Supplementary Search Report for EP 13835702.5 dated Feb. 25, 2016 (8 pages).
EPO; Application No. EP 13835702.5, European Supplementary Search Report dated Jun. 24, 2016 (12 pages).
EPO; Application No. EP 13835702.5, Rules 70(2) and 70a(2) EPC Communication dated Jul. 12, 2016, 2016 (1 page).
PCT; International Preliminary Examination Report dated Jun. 11, 1999 in Application No. PCT/US1998/04086.
PCT; International Preliminary Report on Patentability dated Mar. 10, 2015 in Application No. PCT/US2013/059104.
PCT; International Preliminary Report on Patentability dated Oct. 30, 2007 in Application No. PCT/US2005/045961.
PCT; International Preliminary Report on Patentability dated Oct. 5, 2010 in Application No. PCT/US2009/038988.
PCT; International Preliminary Report on Patentability dated Sep. 19, 2013 in Application No. PCT/US2012/028139.
PCT; International Preliminary Report on Patentability dated Sep. 26, 2006 in Application No. PCT/US2004/022025.
PCT; International Search Report and Written Opinion dated Aug. 27, 2014 in Application No. PCT/US2014/30745.
PCT; International Search Report and Written Opinion dated Jan. 10, 2014 in Application No. PCT/US2013/059104.
PCT; International Search Report and Written Opinion dated Jun. 8, 2009 in Application No. PCT/US2009/038988.
PCT; International Search Report dated Aug. 7, 2006 in Application No. PCT/US 2004/022025.
PCT; International Search Report dated Jul. 14, 1998 in Application No. PCT/US1998/04086.
PCT; International Search Report dated Jul. 30, 2001 in Application No. PCT/US 1999/010917.
PCT; International Search Report dated Jun. 27, 2003 in Application No. PCT/US2003/006086.
PCT; International Search Report dated Oct. 15, 2007 in Application No. PCT/US 2005/045961.
PCT; International Search Report dated Sep. 28, 2012 in Application No. PCT/US2012/028139.
PCT; Search Report and Written Opinion dated Sep. 28, 2012 in Application No. PCT/US2012/028139.
PCT; Written Opinion dated Aug. 7, 2006 in Application No. PCT/US2004/022025.
PCT; Written Opinion dated Oct. 15, 2007 in Application No. PCT/US2005/045961.
Olsvik et al., “Magnetic Separation Techniques in Diagnostic Microbiology”, Clin Microbiol Rev. 7:43-54, 1994.
Inoue et al., “On-chip culture system for observation of isolated individual cells,” Lab on a Chip 1:50-55, 2001.
Rodrigues and Kroll, “Rapid selective enumeration of bacteria in foods using a microcolony epifluorescence microscopy technique,” J Appl Bacteriol. 64:65-78, 1988.
Zhu et al., “Filter-based microfluidic device as a platform for immunofluorescent assay of microbial cells,” Lab Chip 4:337-341, 2004.
Bloem et al., “Fully Automatic Determination of Soil Bacterium Numbers, Cell Volumes, and Frequencies of Dividing Cells by Confocal Laser Scanning Microscopy and Image Analysis,” Appl Environ Microbiol. 61:926-936, 1995.
Bello, M., “Electrolytic modification of a buffer during a capillary electrophoresis run,” J Chromatogr. 744:81-91, 1996.
Jiang et al., “Human Adenoviruses and Coliphages in Urban Runoff-Impacted Coastal Waters of Southern California,” App Environ Micriobiol. 67:179-184, 2001.
Alban et al., “A novel experimental design for comparative two-dimensional gel analysis: Two-dimensional difference gel electrophoresis incorporating a pooled internal standard,” Proteomics 3:36-44, 2003.
Pagola et al., “The structure of malaria pigment β-haematin,” Nature 404:307-310, 2000.
Related Publications (1)
Number Date Country
20160348091 A1 Dec 2016 US
Provisional Applications (1)
Number Date Country
61449824 Mar 2011 US
Continuations (1)
Number Date Country
Parent 14004145 US
Child 15236021 US